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Abstract 
One of the biggest hurdles in clinical therapy is ensuring that drugs have appropriate pharmacokinetic 
profiles; they must traffic to sites of interest and accumulate there at relevant concentrations, but must 
also be eliminated from tissues at a desirable rate. This is especially important in oncology because 
precise tumor locations may be unknown and therapeutics are often toxic to off-target healthy tissues. 
Nanoscale drug formulations provide a useful way to modulate and improve the behavior of drugs within 
biological systems. For example, gold nanoparticles (AuNPs) can be designed with physiochemical 
properties that allow them to traffic from the bloodstream into tumors. Once there, gold can be utilized for 
a number of clinical applications in imaging (e.g., photoacoustic, CT) and therapy (e.g., photothermal, 
radiosensitization). Gold nanoformulations can also provide an excellent platform for delivery of other 
drugs, thereby allowing targeted multifunctional therapy. However, despite their potential utility, gold 
particles have been slow to translate into the clinic. One area of concern is the slow biodegradation of 
gold; AuNPs that are too large for renal excretion (> 5-10 nm) are likely to persist in tissues for months, 
with unknown long-term health consequences. To address this issue, we have developed novel 
nanomaterials comprising ultrasmall gold particles (~2-3 nm) that are incorporated within a larger micelle 
structure (~50-200 nm). The large overall size promotes localization into tumors; however, the use of 
small individual AuNPs improves long-term excretion. In this work, we first present a polymeric micelle 
containing ultrasmall AuNPs with a pH-sensitive coating. These nanoassemblies are stable at neutral pH 
but dissociate in acidic environments (pH 5.0); they demonstrate rapid degradation within cellular 
lysosomes, which contribute to their progressive and substantial in vivo bioelimination. Next, we describe 
a multifunctional nanocluster combining ultrasmall AuNPs with a near-infrared dye, indocyanine green, 
without the need for additional complexing reagents. In an aggressive mouse breast cancer model, 
intravenously-injected clusters accumulate within tumors and enable photoacoustic imaging and 
photothermal ablation, ultimately resulting in significantly improved animal survival. Together, these novel 
clusters present exciting and useful tools for cancer imaging and therapy. 
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ABSTRACT 
 
ENGINEERING NOVEL NANOMATERIALS FROM ULTRASMALL GOLD CLUSTERS FOR USE 
IN CANCER THERAPY 
Elizabeth Marie Higbee-Dempsey 
Andrew Tsourkas 
 
One of the biggest hurdles in clinical therapy is ensuring that drugs have appropriate 
pharmacokinetic profiles; they must traffic to sites of interest and accumulate there at relevant 
concentrations, but must also be eliminated from tissues at a desirable rate.  This is especially 
important in oncology because precise tumor locations may be unknown and therapeutics are 
often toxic to off-target healthy tissues.  Nanoscale drug formulations provide a useful way to 
modulate and improve the behavior of drugs within biological systems.  For example, gold 
nanoparticles (AuNPs) can be designed with physiochemical properties that allow them to traffic 
from the bloodstream into tumors.  Once there, gold can be utilized for a number of clinical 
applications in imaging (e.g., photoacoustic, CT) and therapy (e.g., photothermal, 
radiosensitization).  Gold nanoformulations can also provide an excellent platform for delivery of 
other drugs, thereby allowing targeted multifunctional therapy.  However, despite their potential 
utility, gold particles have been slow to translate into the clinic.  One area of concern is the slow 
biodegradation of gold; AuNPs that are too large for renal excretion (> 5-10 nm) are likely to 
persist in tissues for months, with unknown long-term health consequences.  To address this 
issue, we have developed novel nanomaterials comprising ultrasmall gold particles (~2-3 nm) that 
are incorporated within a larger micelle structure (~50-200 nm).  The large overall size promotes 
localization into tumors; however, the use of small individual AuNPs improves long-term 
excretion.  In this work, we first present a polymeric micelle containing ultrasmall AuNPs with a 
pH-sensitive coating.  These nanoassemblies are stable at neutral pH but dissociate in acidic 
environments (pH 5.0); they demonstrate rapid degradation within cellular lysosomes, which 
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contribute to their progressive and substantial in vivo bioelimination.  Next, we describe a 
multifunctional nanocluster combining ultrasmall AuNPs with a near-infrared dye, indocyanine 
green, without the need for additional complexing reagents.  In an aggressive mouse breast 
cancer model, intravenously-injected clusters could accumulate within tumors and enable 
photoacoustic imaging and photothermal ablation, ultimately resulting in significantly improved 
animal survival.  Together, these novel clusters present exciting and useful tools for cancer 
imaging and therapy. 
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CHAPTER 1: INTRODUCTION TO GOLD NANOPARTICLES IN BIOLOGICAL 
SYSTEMS 
 
1.1 Overview of nanoparticles 
Introduction to nanomaterials 
Nanoparticles are discrete units of matter that behave as a single entity 
(“particles”) and possess dimensions in the scale of 1 to 1000 nm (“nano”).  
Nanoparticles demonstrate unique attributes as a material.  Like molecules, their small 
size confers high mobility and high specific surface area[1]; however, like bulk materials, 
they can possess useful ensemble features[2] including mechanical,[3] magnetic[4], 
optical,[5] electric, and thermal properties.  As a result, nanomaterials have been 
increasingly explored in both the physical and life sciences.  In biological systems, they 
show great promise for the diagnosis, treatment, and prevention of disease. 
Nanomaterials can be broadly classified by a number of intersecting categories, 
the most common of which are based on component materials (organic vs. inorganic, 
biologically-derived material vs. synthetic).  Other important distinctions include shape 
(spherical vs. nonspherical); preparation route (chemical vs. physical/mechanical vs. 
biological, bottom-up vs. top-down); and a range of morphological features (size, 
structure) and functional applications.[6–8]   
Gold nanoparticles 
Gold nanoparticles (AuNPs) are among the oldest-known and best-studied 
nanoformulations.[9]  Gold is a highly useful material with unique physiochemical 
properties: high atomic number, surface plasmon resonance, redox behavior, 
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conductivity, optoelectronic properties, etc.[10,11]  AuNPs can be synthesized in a wide 
range of sizes (from smaller than 1 nm to larger than 500 nm), as well as a range of 
shapes (including spheres, rods, stars, triangles, boxes, shells, and cages), and under 
mild reaction conditions (typically atmospheric oxygen and moderate temperatures).  
Gold surfaces can also be easily functionalized with self-assembled monolayers of 
thiols, due to the favorable bond formed between gold and sulfur. [12–14]  By this method, a 
wide range of thiolate materials have been used to coat AuNP surfaces, including: 
alkanes, polymers, antibodies and other proteins, and oligonucleotides.[11] 
1.2 Gold nanoparticle formulations 
Synthesis of gold cores 
The classical method of AuNP synthesis was described in 1951 by Turkevich et 
al.[15]  In this method, tetrachloroauric acid is reduced by trisodium citrate in boiling 
water, yielding gold spheres with hydrophilic citrate-stabilized surfaces.  This original 
protocol produced 15-20 nm gold spheres; a later breakthrough by Frens et al in 1973 
determined that the gold-to-citrate ratio could be manipulated in order to generate a 
range of particle sizes, from 16 to 147 nm.[16]  Other refinements have included the use 
of alternate reducing agents (e.g. ascorbate, UV irradiation) that improve the spherical 
definition of particles.[17] 
In 1994, Brust and Schriffin reported a landmark strategy for producing 
hydrophobic gold spheres.[18]  In a two-phase system, using tetraoctylammonium 
bromide as a phase transfer reagent, gold salt is reduced by sodium borohydride and 
coated with alkanethiols.  Particles produced by this method have the advantage of 
ultrasmall size (approximately 1-5 nm), as well as high stability conferred by the ligand 
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coating; these thiols form a monolayer that strongly associates with the gold surface 
through Au-S bonds and with neighbor thiols through van der Waals interactions. [13,19] 
Many other innovative syntheses have been reported that greatly expand the 
repertoire of gold nanoparticles.  Some examples include: using ammonium surfactants 
to form gold nanorods, which have unique resonant properties and biological 
interactions;[20–22] the formation of gold nanoshells, which exhibit tunable optical 
properties based on their size;[23–25] and the creation of ultrasmall (< 2 nm) gold 
nanoparticles, including those with known atomic structure and molecule-like properties 
such as photoluminescence.[26,27] 
Conjugation and surface coating 
The surface composition of AuNPs can be tailored by using one or several 
general strategies (Figure 1.1).  
 
Figure 1.1.  Modulation of gold surfaces can follow several different schemes.  Adapted by permission from 
Love et al.[13]   
As noted, gold particles complex with surface ligands during their formation; 
these may be weakly-associated stabilizing agents like citrate, phosphines, and 
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amines[28–30] or strongly-bound thiols.  Many AuNP formulations have been developed 
with the specific goal of incorporating desired ligands during initial synthesis, often using 
biologically relevant molecules: glutathione,[31,32] coenzyme A,[33] tiopronin (a 
pharmaceutical),[33] ethylene glycols,[34–36] and others.[13] 
If the desired ligand cannot be directly incorporated, it can sometimes be 
generated by chemical modification of surface ligands.  A very common reaction 
technique is through peptide coupling.[37–39]  Classic organic mechanisms can also be 
employed, such as alkene metathesis,[40] nucleophilic substitutions,[41] and click 
chemistry.[42,43]   
Alternatively, an existing surface ligand may be displaced by a new ligand.  This 
approach is used to confer long-term stability on citrate AuNPs and other non-thiolated 
gold particles.  Exchange can occur rapidly through simple mixing, though occasionally 
an intermediary ligand is introduced (e.g., Tween 20, lipoic acid) to minimize potential 
aggregation of particles).[44,45]  Another intermediary ligand, 4‐dimethylaminopyridine 
(DMAP), has been used to transition particles from hydrophobic to hydrophilic in a four-
stage process: 1) particles are synthesized by the Brust method in the absence of 
alkanethiols; 2) the resulting amine-stabilized particles undergo ligand exchange with 
DMAP; 3) DMAP acquires a positive charge and confers water solubility on the particle; 
and 4) particles can then undergo additional ligand exchange reactions with hydrophilic 
thiols in aqueous media.[29]  Ligand exchange can also occur on particles that are 
already coated with thiolates.  This exchange occurs by associative substitution – that is, 
an incoming thiol (or disulfide) displaces a bound thiolate by way of a short-lived 
intermediate complex, similar to nucleophilic attack reaction/mechanisms.[41,46–48]  By 
equilibrating thiolated particles with an excess of the desired thiol (typically a 10-fold 
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molar excess), near- to complete-exchange can occur.  This method can also be used to 
decorate particle surfaces with a heterogeneous mix of materials. 
Larger assemblies  
Gold particles have also been incorporated into a variety of large, complex 
structures, often involving noncovalent interactions such as electrostatic and protein-
substrate (e.g., avidin-biotin).[49,50]  One common noncovalent method is to encapsulate 
hydrophobic AuNPs using amphiphilic materials that thereby confer water solubility 
without chemical modification.  Amphiphilic materials can be natural or synthetic (e.g., 
lipids, polymers, proteins, small molecules).  Based on their properties, and especially 
their amphiphilic mass ratio, they can form a variety of structures.  Common examples of 
structures include micelles (monolayer of amphiphiles) and vesicles like liposomes and 
polymersomes (bilayer of amphiphiles).  As an advantage, these macrostructures allow 
the incorporation of multifunctional materials within a single moiety, without the need for 
complex synthetic conjugation strategies; this has been demonstrated to great effect as 
a strategy to co-encapsulate therapeutic compounds, allowing delivery of multiple 
synergistic pharmaceuticals or allowing concomitant imaging and treatment of 
disease.[51]   
1.3 Nanoparticle behavior in biological systems 
Introduction to nano-bio interactions 
Nanoparticles, including AuNPs, exhibit unique behavior within biological 
systems.  This behavior is often critical to their clinical utility over other materials, and yet 
it can be difficult to fully understand and control these complex interactions.  To achieve 
their full efficacy, it is often necessary for particles to reach specific tissues, cell types, or 
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even subcellular compartments, while avoiding off-target locations.  There must also be 
control over dosage and kinetics, as well as considerations of their eventual degradation 
and/or elimination.  Evaluations of nano-bio interactions must include both an accounting 
of the particle’s physiochemical properties – size, shape, composition, etc. – as well as 
understanding of the biological environments on molecular, cellular, and organismal 
scales. 
1.3.1 Molecular interactions 
When nanoparticles enter physiological environments, such as after intravenous 
injection, they interact with proteins that non-specifically adsorb to their outer surface 
due to high surface free energy.[52,53]  This protein corona forms rapidly[54] and consists of 
two temporal and spatial phases.  Initially, the nanoparticle will be surrounded by a “soft” 
corona wherein the highest-abundance proteins associate dynamically with the particle 
surface; after longer exposure, the innermost layer of proteins will be displaced by those 
with the highest binding affinity, and this “hard” corona may be irreversibly bound to the 
particle surface.[55,56]  It has been proposed that the protein corona is what the cell truly 
“sees”, and therefore studies of the nano-bio interface should consider it as equally or 
more important than the particle’s bare surface composition.[57]   
The composition of the protein corona is greatly influenced by the 
physiochemical makeup of the nanoparticle.[55]  Because such a large number of 
parameters contribute to these interactions, it is often highly difficult to assess their 
relative contributions; still, some general trends have been reported.  For example, a 
number of studies[58–61] – including several landmark proteomics studies reported by 
Tenzer et al[54,62] – have demonstrated that protein identity and relative abundance vary 
with particle size and surface charge.  Corona proteins can also undergo conformational 
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changes, particularly upon association with hydrophobic particles,[63] positively-charged 
particles,[64] strongly-negatively-charged particles,[65] and rod-shaped particles.[66]  
Greater quantities of adsorbed proteins (i.e., thicker coronas) have been seen on larger 
particles[60], hydrophobic particles[67], particles with rough surfaces,[68] and on rod-shaped 
particles compared to spheres.[69]  Biological contributions are also highly important, 
even within a single medium such as serum.  For example, the identities of adsorbed 
corona proteins can change based on serum concentrations (such as those used for 
typical in vitro experiments vs. in vivo),[70] and differences very likely occur between 
species, disease states, and individuals.  Furthermore, variations in the protein corona 
are likely to have a direct impact on interactions between nanoparticles and cells, 
including pharmacokinetics, toxicity, and cell selectivity.[54] 
1.3.2 Cellular interactions 
Particle properties greatly affect interactions with cells, both through coronal 
variations and more generally.  For example, positively charged nanoparticles tend to 
have faster cellular uptake and higher cytotoxic potential, even after complexing with 
serum proteins.[65]  The enormous impact of surface charge typically arises from the 
interaction between particles and the phospholipid head groups and protein domains 
found on the cell membrane; generally, positive nanoparticles have greater associations 
with the largely negative lipids found on the cell surface, though the impact of this on cell 
uptake varies between cell lines.[71]  Other cell surface elements can contribute to this 
interplay, including glycans (which may act as a barrier) and specific membrane 
proteins. 
Endocytosis 
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Nanoparticles typically enter cells through endocytosis.[72–74]  In this process, 
extracellular material is enveloped by cellular membrane; these cavities then pinch off 
from the outer plasma membrane to form intracellular vesicles that are broadly known as 
endosomes (Figure 1.2).  Endosomes transport material throughout the cell and into 
other specialized vesicular compartments, including other endosomes.  A range of 
different types of endosomes are defined by their unique protein markers and distinct 
functions.  A common target for nanoparticles and other materials is the so-called early 
endosome.[72,73] 
 
Figure 1.2.  Mechanisms of endocytosis and intracellular vesicle trafficking.  Reproduced by permission 
from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature Reviews Molecular Cell 
Biology, Mayor and Pagano, 2007.[75] 
Phagocytosis 
Phagocytosis, or cellular “eating”, is typically performed by specialized cell types, 
termed professional phagocytes, which include macrophages, neutrophils, monocytes, 
dendritic cells, and mast cells.  These cells are responsible for engulfing large cargo 
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(e.g., pathogenic organisms, cellular debris, and aged cells), performing a critical role in 
immunity and tissue homeostasis.  Phagocytosis can also be performed 
“nonprofessionally” by several other cell types, including fibroblasts, epithelial cells, and 
endothelial cells.  Their phagocytic functions tend to be more restricted, such as in time 
(e.g., during development) or by target (e.g., apoptotic bodies only). [76–78] 
Cargo is tagged for phagocytosis through affiliation with phagocyte surface 
receptors.  This molecular recognition may occur either by direct recognition of cargo 
features or through intermediary proteins bound to cargo surface.  These latter proteins, 
known as collectively as opsonins, include proteins from adaptive immunity 
(immunoglobulins) and innate immunity (complement proteins) as well as other 
circulating proteins.[79,80]  Binding of cargo to the phagocyte surface triggers activation of 
cytoskeletal actin and extension of cellular pseudopodia, which envelop particles and 
form phagosomes.[78] 
Pinocytosis 
Many other forms of endocytic uptake can be classified as pinocytosis, or cellular 
“drinking”.  Unlike phagocytosis, these processes are performed by many eukaryotic cell 
types.  In the process known as macropinocytosis,[81,82] actin-driven pseudopodia extend 
outward from the cell and then fold back towards the cell surface, engulfing pockets of 
extracellular fluids and their contents.  Adsorptive pinocytosis, sometimes called fluid-
phase endocytosis, involves the uptake of molecules that interact with the membrane 
through nonspecific hydrophobic and/or electrostatic interactions.  After internalization of 
these vesicles, intracellular trafficking tends to be relatively slow compared to higher-
affinity, receptor mediated endocytosis.[83] 
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Specific macromolecular cargo can be recognized by specialized cell surface 
receptors and internalized through receptor-mediated endocytosis.  One such pathway 
uses proteins called clathrins that line the interior of the plasma membrane in localized 
receptor-rich regions and induce inward curvature.[84]  In mammalian cells, clathrin 
endocytosis is responsible for the uptake of key moieties including cholesterol (via low-
density lipoprotein)[85] and transferrin.[86]  Although clathrin endocytosis is the canonical 
pathway of receptor-mediated uptake, clathrin has also been implicated in fluid phase 
endocytosis. 
Another common receptor-mediated pathway involves membrane invaginations 
called caveolae; these are formed from associations of caveolin and cavin proteins with 
highly hydrophobic, cholesterol-enriched membrane domains.[87,88]  After membrane 
scission, budded caveolae may fuse with early endosomes or with specialized 
compartments called caveosomes;[89] these vesicles are distinct from early endosomes 
in that they are pH neutral and they can bypass the early endosome’s downstream cargo 
degradation pathways.[90]  Caveolae have also been implicated in transcytotic trafficking 
across polarized cells including vascular endothelial cells,[91,92] though other data is 
mixed.[93,94] Both clathrin- and caveolae-mediated endocytosis canonically utilize the 
GTPase dynamin for scission of vesicles from the plasma membrane [95–97].   
Several other receptor-mediated pathways have been reported that utilize neither 
clathrin nor caveolae.  Though characterization of their mechanisms and specificity is 
underdeveloped, several of these pathways are identified by their association with 
particular small GTPases.[75,98]  The RhoA-regulated pathway, which also employs 
dynamin for scission, has been implicated in the uptake of interleukin-2 and several 
other cytokines.  The Cdc42-regulated and ARF6-regulated pathways differ from the 
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other receptor-mediated pathways described in that they do not use dynamin, and they 
traffic to distinct types of endosomes – GPI-AP-enriched early endosomal compartments 
(GEECs)[99,100] or tubular recycling endosomes,[101,102] respectively.    
Nanoparticle internalization 
All of the described endocytic mechanisms have been associated with 
nanoparticle uptake, though certain forms predominate.  As with the formation of the 
protein corona, cellular interactions with nanoparticles can vary greatly depending on 
nanoparticle form and composition.  Indeed, the protein corona itself can strongly 
mediate these interactions, since a number of endocytic mechanisms involve binding 
specific proteins (e.g., immunoglobulins for phagocytosis, albumin for receptor-mediated 
endocytosis).  Multiple contributions may also be difficult to deconvolute, and can even 
seem contradictory; for example, large elongated particles may have stronger 
membrane interactions through higher binding valency, but also require more membrane 
deformation for internalization.[103]  Variations that seem minor can have a large impact; 
for example, one study found that increasing particle diameter from 100 nm to 200 nm 
could switch uptake from clathrin- to caveole-mediated mechanisms.[104] 
A commonly discussed phenomenon is the discrepancy of nanoparticle size with 
receptor-mediated endocytosis.  A single flask-shaped caveolae has a diameter of 60-80 
nm, and the typical size of a clathrin-coated pit is 60-120 nm.[84,90]  However, a number of 
studies have demonstrated strong evidence for these pathways’ involvement in uptake 
of very large nanoparticles.  Notably, several bacterial strains appear to use these 
pathways, despite their micrometer size.[105] 
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Nanoparticles may be directed towards a specific cell type or cell internalization 
mechanism through active targeting.  For example, placement of folate on particle 
surfaces has been used to accumulate nanomaterials in cancer cells overexpressing 
folate receptor, and encourage particle internalization through caveolae.[106,107]  
Abraxane®, one of the earliest-approved and most successful nanomaterials, contains 
albumin that is designed to promote transcytosis across the vascular wall via caveolae-
mediated mechanisms.[108,109] 
Endosomal trafficking 
As mentioned, the destination for many pinocytic vesicles is early endosomes, 
where the engulfed material is separated and sorted.[72,73]  For example, membrane 
receptors can be dissociated from their bound cargo due to the endosome’s acidic 
internal environment (pH 6.0 to 6.2), which is maintained by resident V-ATPase proton 
pumps.[110,111]  The majority of membrane proteins are recycled back to the outer 
membrane.  Material destined for degradation is then packaged into trafficking vesicles, 
transported along microtubules towards the cell center, and fused with late endosomes.  
Late endosomes are more acidic (pH 5.5 to 6.0) and contain hydrolytic enzymes; these 
vesicles fuse with and mature into lysosomes, which have increased acidity (pH 4.5 to 
5.0) and a large cohort of lytic enzymes.[112] 
Phagosomes undergo a similar maturation process involving progressive 
acidification and changes in enzymatic content.[78,113]  Phagosomes have fusion events 
with early endosomes, transitioning into late phagosomes while moving along 
microtubules towards the cell center.  Finally, late phagosomes fuse with lysosomes to 
form phagolysosomes.[113]  Phagolysosome composition can vary significantly between 
different phagocyte types.  For example, they are highly acidic (as low as pH 4.5) in M2 
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macrophages, which are primarily responsible for clearing apoptotic and necrotic 
material.  However, phagocytes involved with elimination of pathogens, such as M1 
macrophages and neutrophils, undergo a slower rate and/or lower extent of acidification; 
this has been attributed to a number of mechanisms[114,115] including delayed fusion with 
lysosomes, fewer copies of V-ATPase, leakage of protons through increased 
phagosome membrane permeability, and consumption of protons by superoxide.  In 
these cells, reduced lysosomal acidity is associated with greater production of reactive 
oxygen species (through the activity of NADPH oxidase) and highly effective 
antimicrobial activity.[113,115] 
Notably, some endocytic vesicles (e.g., caveosomes) – can bypass these 
pathways; this phenomenon is exploited by a number of pathogens,[89,90,105,116,117] and 
could be used as a mechanism for delivering therapeutics while avoiding their lysosomal 
degradation.[109,118] 
Cytosolic entry 
For many important therapeutic targets, nanoparticles (and other drugs) must 
reach the cytoplasm.  The advantages of this include: delivery of cytosolically active 
agents, such as proteins and nucleic acids; ability to interact with native cytosolic 
structures, such as organelles; and avoidance of negative endosomal/lysosomal effects, 
including quenching of imaging agents[119–121] and degradation of materials.  In order to 
access the cytosol, particles have been designed to traverse the lipid membrane using 
several strategies.   
Particles that are very small (1-4 nm) – or, very small in at least one dimension – 
may be capable of directly penetrating the plasma membrane. [122,123]  To deliver larger 
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particles, a common strategy is coating particle surfaces with cell penetrating peptides; 
as their name suggests, these short (5-30 amino acids) and typically net-cationic 
peptides are capable of passing through cell membranes, often without overt membrane 
disruption.[124–126]  This method has been used to deliver gold nanoparticles[127] and a 
variety of other nanomaterials like iron oxide nanoparticles,[128] liposomes,[129–132] and 
polyplexes.[133]  Particle surfaces can also be designed to mimic physiochemical features 
of cell penetrating peptides, such as an ordered arrangement of hydrophobic and ionic 
groups.[134] 
Other techniques for cytosolic delivery involve escape from intracellular 
endosomes.  One such strategy, dubbed the “proton sponge” method,[135–137] involves 
loading endosomes with nanomaterials that possess high proton buffering capacity 
(usually titratable polyamines).  As these materials sequester endosomal protons, they 
can swell due to intramolecular electrostatic repulsion; at the same time, the continued 
activity of V-ATPase pumps will result in progressive accumulation of 1) chloride ions, 
which passively influx to balance transmembrane voltage, and 2) water, due to the 
resulting osmotic pressure.  These two forces cause endosomes to rupture, allowing 
leakage of nanoparticle cargo into the cytosol.[136,138]  Another endosomal escape 
strategy employs a different class of peptides known as membrane-destabilizing 
peptides or endosome-disrupting peptides.  These peptides, many of which are derived 
from viral proteins, trigger membrane disruption in response to endosomal 
environmental cues such as low pH,[139,137] allowing escape of associated nanoparticles 
and other cargo.[140,141]  Importantly, methods of cytosolic entry may result in cytotoxicity 
due to disruption of the outer membrane (hole formation and/or membrane thinning).[142]  
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1.3.3 Organismal interactions 
The majority of nanomedicines are designed to be injected as a bolus into 
peripheral veins.[143]  Their initial interactions within the bloodstream will therefore include 
the vascular endothelial cells that line vessel walls, but will also include circulating cells 
(erythrocytes, leukocytes, and platelets) and circulating proteins (albumin, globulins, 
fibrinogens, and regulatory proteins).[60,144,145]  Particles may also be marginated to 
different areas of the vessel cross section (i.e., towards the outer walls) due to fluid 
tumbling dynamics and interactions with other circulating materials.[146]  As particles are 
carried to the heart, they will first encounter capillary beds within the lungs; this may 
cause very large particles to become deposited there.  Other/smaller particles will enter 
the arterial system and move into organs (Figure 1.3).  
 
Figure 1.3.  Potential trends in nanoparticle distribution based on size, shape, and surface charge.  
Reproduced by permission from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature 
Biotechnology, Blanco et al, 2015.[147] 
 
Healthy vasculature 
Much of the body’s vasculature consists of continuous endothelium, with 
nonfenestrated endothelial cells connected via tight junctions and adherens junctions.[148]  
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Due to their size, most nanomaterials are unable to pass between these cells, so can 
only exit these vessels and enter tissues by endocytic uptake through cells, i.e. 
transcytosis.  However, within some tissues, endothelial cells contain small constitutive 
holes called fenestrae.[148]  In organs such as the kidney, these openings (approximately 
60-80 nm) are effectively narrowed to 5-6 nm by filamentous diaphragms; by contrast, 
the liver and spleen contain larger sinusoidal gaps (approximately 100-250 nm), no 
diaphragms, and a discontinuous basement membrane.[144,148,149]  As blood passes 
through these vessels, nanoparticles can leak out of pores and accumulate within these 
organs in a matter of minutes, being effectively filtered by size.[143,147]   
Organs compartments 
Once particles leave fenestrated vessels and enter an organ, they must perfuse 
through the extracellular microenvironment and its assortment of matrix proteins and 
glycans (e.g., laminin, collagen) which have the potential to impede diffusion of 
nanoparticles.[146,150,151]  In the liver and spleen, particles will encounter large populations 
of resident tissue macrophages that comprise the mononuclear phagocyte system 
(MPS, formerly known as the reticuloendothelial system, RES).[152,153]  These tissue 
macrophages are often the dominant consumers of intravenously-administered 
nanoparticles. 
Spleen 
The spleen plays a major role in filtration and elimination of pathogenic 
organisms and aged erythrocytes; nanomaterials can be similarly scavenged due to 
shared characteristics (i.e., nano size, opsonization, and low deformability).[146,154,155]  
Studies in rodents have found that smaller nanoparticles (15-200 nm) tend to be taken 
up by a subset of macrophages found in the spleen’s marginal zone (the junction 
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between red and white pulps),[156,157] while larger particles end up in red pulp 
macrophages.[158]  Notably, human spleens have different architecture (e.g., no marginal 
zone and different macrophage subtypes), so studies performed in rodents and other 
animals may not accurately reflect nanoparticle behavior in humans.[159,160]  
 
Liver 
Like the spleen, the liver sequesters pathogens and aged red blood cells; it also 
has a special role in elimination of large lipoprotein particles (> 200 nm) called 
chylomicrons.[144,148,161]  The liver’s resident macrophages, termed Kupffer cells, form the 
body’s largest reservoir of tissue macrophages (often reported as 50-80%).[162,163]  These 
cells commonly internalize large fractions of nanoparticles, particularly opsonized 
particles.  Notably, particles can also be taken up by hepatic sinusoidal epithelial cells, 
which tend to have high endocytic activity; it has been proposed that these are a major 
source of receptor-mediated endocytosis.[148,164,152] 
Kidney 
In the kidney, blood passes through renal filtration structures called glomeruli 
(which exclude material larger than 5-6 nm) and flows into tubules; fluid and metabolites 
are then re-collected by renal veins, while remaining waste material flows through the 
ureter into the bladder.[165]  The kidney thereby collects nanomaterials that are smaller 
than 5-6 nm (including high-aspect-ratio particles with two small dimensions).  Notably, 
small particles must also have low opsonization, or else they will likely be diverted by the 
MPS.[146,165–167]   
Diseased vasculature 
18 
 
While vascular leakage is fundamental for the healthy filtration functions of the 
mentioned organs, leaky endothelial beds can also arise in several diseased states.  For 
example, inflammation increases vessel permeability, which facilitates migration of 
immune cells from blood into diseased tissue[168] and can also be exploited to deliver 
nanotherapeutics.[169]   
Abnormal vascular fenestrations are also famously associated with cancer.  As 
tumors grow beyond 2-3 mm in diameter and surpass limits for nutrient diffusion, they 
must establish an independent blood supply.[168,170,171]  However, this angiogenic process 
is highly dysregulated, and the resulting vessels are often characterized by tortuous 
branching, uneven dilation, abnormal deposition of mural cells and basement 
membranes, and gaps between endothelial cells (most 1-100 nm, up to almost 5 
µm).[172–175]  Through these gaps, circulating nanomaterials can extravasate from the 
bloodstream and into tumor tissue.[151]  Furthermore, the intratumor environment typically 
lacks functional lymphatic vessels,[176] so particles may not be able to drain away from 
tissues quickly.  These two phenomena are known collectively as the enhanced 
permeability and retention (EPR) effect,[177] and are the theoretical basis for the 
observation that long-circulating nanomaterials can accumulate in tumor tissue on the 
basis of size alone.  The majority of FDA-approved nanoparticles for oncology have 
been designed based on this principle, without molecular targeting. 
However, several challenges are associated with this strategy.  It can be difficult 
for particles to permeate far away from blood vessels – indeed, the lack of lymph 
drainage within the tumor also causes high interstitial pressure that may prevent inward 
diffusion of particles[178,179]  This is especially important considering many tumors may 
have large sections that are poorly vascularized, and some cancer types (e.g., prostate) 
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are prone to low vascular density overall.[179,180]  Also, while particle accumulation may 
be higher than that of small molecular compounds, the overall dose fraction delivered to 
the tumor is often still quite low.  In a landmark meta-analysis performed by Wilhelm et 
al,[181] it was found that tumors received a median of only 0.7% of the injected dose. 
Also, though EPR has been observed consistently in animal models, these may not 
accurately reflect the typical clinical presentation, especially when xenograft models are 
used for establishing tumors.  In humans, the extent of EPR may be highly variable 
between different tumor types, in different patients, in metastases, and even within a 
single tumor.[182]  Nevertheless, EPR can be an effective tool for delivery of 
nanomaterials. 
1.3.4 Degradation and elimination 
By lysosomal pathways, a large portion of ingested material – including 
nanomaterials – are degraded by the cell.[183]  Nanoparticles and their breakdown 
products can exit the body through renal and/or hepatobiliary excretion pathways.[184]  
Particles that accumulate in the kidneys and pass through renal filters are then collected 
in the urine, where they can be eliminated.[165]  Within the liver, particles can be 
endocytosed by hepatocytes; these cells periodically exocytose the contents of their 
lysosomes into bile, which eventually carries this material into the duodenum and into 
feces.[185–187]  As mentioned, most particles that enter the liver are sequestered in Kupffer 
cells (at least, preliminarily), and therefore must avoid or escape these cells in order to 
undergo hepatobiliary excretion.  Additionally, while renal clearance generally occurs 
within minutes, hepatobiliary excretion has a timeline of weeks to months. [186] 
Many organic materials are lysosomally digested.  For example, dextran can 
degrade over the course of several weeks, eventually being excreted through the 
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urine.[188]  Degradation of organic materials commonly occurs via lysosomal hydrolytic 
enzymes, though they can also be degraded by reactive oxygen species; interestingly, 
this process can take place intracellularly[189,190] or extracellularly.[191,192]  Some inorganic 
materials can be degraded within lysosomes, generally through acidic mechanisms. [193]  
An excellent example is iron oxide nanoparticles; in vivo studies have demonstrated their 
breakdown in lysosomes and incorporation into the body’s iron store – first in 
intracellular ferritin, eventually in RBC hemoglobin – potentially without disrupting cellular 
iron homeostasis.[188,194–196] 
However, gold nanoparticles present a great challenge for biodegradation.  They 
have very limited breakdown within the body, and numerous studies have shown 
persistence of gold for long timeframes in organs such as the liver.[197–200]  It does appear 
that some gold nanoparticle formulations can break down over time.[194]  One proposed 
mechanism is through etching by hydroxyl radicals, which can be produced by 
macrophages;[201–203] it may also be possible for surface-bound thiols to dissociate from 
gold cores and pull out individual Au atoms as they migrate.[204,205]  Occasionally, the 
robustness of gold has been utilized purposefully, such as to protect other nanomaterials 
from degradation.[206]  However, it is generally considered a hurdle for clinical 
translation.[207,208] 
1.3.5 Other physiochemical interactions 
Stimulus-responsive nanoparticles 
The complexity of biological systems presents unique challenges in that 
materials must often navigate multiple compartments over time; a particle’s 
physiochemical properties may be advantageous at one stage and unfavorable in 
another.  To address this issue, a number of reported nanoformulations have been 
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designed to respond to environmental changes in order to produce different 
spatiotemporal effects.   
One source of useful triggers is the cohort of different physiochemical conditions 
present within the body.  For example, pH gradients exist between many tissues and 
subcellular compartments.  As previously mentioned, cellular endosomes and lysosomes 
are typically acidic; solid tumors may also have reduced extracellular pH (as low as 6.5) 
due to hypoxia, lactate production, and related effects.[209,210]  Nanomaterials may 
respond to these conditions through changes such as protonation or hydrolysis.[211,212]    
Some examples of triggered effects include, but are not limited to: electrostatic swelling 
or membrane fusion to rupture endosomes,[138,213] cleavage to release covalently-bound 
drug cargo or expose surface ligands,[214,215] solubility transitions that allow dispersion of 
cargo and/or particle degradation;[216,217] and aggregation or dissociation for tumor 
retention or penetration, respectively.[218]  In addition to pH-triggered events, many other 
endogenous stimuli can be targeted to induce similar changes in particles.  Within 
tumors, stimuli could potentially include enzymes (especially proteolysis),[219–222] redox 
changes (especially disulfide reduction),[223–225] and temperature (hyperthermia).[226] 
Particles have also been designed to react to exogenously-applied triggers.  
These often have the advantage of additional control over the site, time, and intensity of 
administration.  For example, rather than relying on the minor hyperthermia present in 
some diseased tissue, temperature can be directly increased through mechanisms such 
as highly-focused ultrasound.[227,228]  Nanomaterials themselves may generate heat in 
response to triggers like irradiation and ultrasound,[229–235] which can be used for 
applications such as therapeutic tissue ablation or enhanced release of other cargo. 
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Toxicity 
 As described in detail, nanomaterials interact uniquely with biological systems in 
ways that are distinct from their composite materials’ molecular or bulk properties.  This 
principle applies to toxicity as well.  Materials can have distinctive safety profiles based 
on factors that include their physical presentation within a particle structure, their 
combination with other incorporated substances, or their particle-related degradation 
profiles.  A number of studies have looked at the toxicity of gold nanoparticles, but it is 
clear that results can vary widely.[200,236–238]  General mechanisms of toxicity include 
oxidative stress,[65,239,240] cytoskeletal changes,[65,239,240] upregulation of proinflammatory 
cytokines,[241,242] and membrane lysis.[239]  Toxicity can also be associated with 
persistence of AuNPs within lysosomes; their presence may cause alkalization and 
inhibition of lytic enzymes within lysosomes, and can disrupt autophagosome-lysosome 
fusion.[243,244]   
Unsurprisingly, toxicity appears to depend greatly on the surface coating of 
particles.  Several early studies demonstrating toxicity in gold particles – especially 
nanorods – were ultimately found to be the result of surface-associated 
cetyltrimethylammonium (CTAB), which is commonly used in particle synthesis and 
which can cause mitochondrial damage and apoptosis.[245,246]  In animal studies, citrate-
coated particles were found to be more biocompatible than particles coated with a 
common solubilizing peptide, CALNN, which produced anemia and atrophy of the 
spleen.[199]  Notably, surface composition has a large impact on protein corona and on 
membrane interactions, both of which can contribute to the apparent toxicity of particles.  
For example, studies showed greater dose-dependent toxicity for cationic particles than 
for anionic particles, but this may have been the effect of their greater cellular 
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association and/or uptake.[65,239]  An interesting study by Soenen et al[240] also reported 
that positively-charged particles could induce toxicity, while neutral PEG-coated particles 
were less toxic; however, when data was normalized by intracellular nanoparticle levels, 
PEGylated particles were found to have greater induction of ROS.  Another property that 
modulates toxicity is particle size, though these trends are especially variable between 
studies; particles have been separately described as toxic only in the range of 8-37 
nm;[247] only in the range of 1.2-1.4 nm;[248] or only below 6 nm.[241]   
However, a large number of studies have found AuNPs to be generally 
nontoxic.[59,237,249–251]  Mouse studies using AuroVist™ (1.9-nm water-soluble AuNPs) 
have reported an LD50 as high as 3.2 g kg-1 body weight.[252]  Other studies have shown 
excellent tolerance for chronic high doses of AuNPs (up to 550 µg kg-1 per day for up to 
28 days).[253,254]  One of the most comprehensive studies was performed by Gad et al, [198] 
who tested PEGylated 155-nm gold shells (AuroLase®) and showed no acute or chronic 
toxicity in mice or dogs.  These data formed the basis for clinical trials involving 
photothermal ablation of prostate tumors, and the particles’ clinical safety in patients was 
confirmed.[255,256]  Overall, it is clear that many AuNPs can exhibit excellent 
biocompatibility, though new formulations must be rigorously tested. 
1.4 Applications for gold nanoparticles in cancer 
Cancer 
Cancer, which is characterized as the malignant uncontrolled growth of cells, 
remains one of the world’s leading causes of death.  Treatment paradigms typically 
include surgery to remove solid tumors, as well as a combination of chemotherapy and 
radiation to induce cellular death.  All three of these areas have been explored heavily in 
nanoparticle applications, including image-guided surgery to reveal tumor location and 
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define margins; delivery of toxic compounds to tumors; and localized radiation dose 
enhancement.[257,258] 
Breast cancer is the most common type of cancer in women, with 1.4 million new 
cases diagnosed annually worldwide.[259]  While the incidence of breast cancer has been 
steadily increasing globally, it has decreased over the last decade in the United States. 
This decrease correlates with the introduction of hormone-replacement therapy, which 
has proven effective in treating estrogen receptor-positive tumors.  However, nearly 10-
20% of tumors lack the ability to respond to hormone therapy.[260]  These tumors tend to 
be more aggressive, consequently requiring more aggressive regimens of cytotoxic 
chemotherapy, surgery (where possible), and radiation.[261]  The use of targeted 
nanomedicines could potentially facilitate enhanced treatment of breast cancer without 
increasing adverse side effects.[262,263] 
1.4.1 Imaging applications 
Computed tomography 
 Computed tomography, or CT, is a highly efficient and widely available tool for 
imaging tumors and other biological tissues.[264]  CT imaging involves the three-
dimensional reconstruction of images produced by x-rays.  Tissues attenuate x-rays to 
different degrees based on several factors including thickness and mass attenuation 
coefficient; this value is derived from the photoelectric effect, which proportional to the 
cube of the material’s atomic number (Z3).  Many soft tissues are difficult to differentiate 
due to their similar degrees of x-ray attenuation, but they can be distinguished by 
administering contrast agents with variable distribution.  Gold nanoparticles have 
excellent potential as a CT contrast agent due to gold’s high atomic number (79) and 
AuNPs’ distinct pharmacokinetics.[238,264,265]  Early uses of AuNPs in x-ray imaging were 
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reported in 2004 and 2006 by Hainfeld et al.[266,252]  These studies using 1.9-nm AuNPs 
produced detailed images of blood vessels (including vascularized tumors), with greater 
and longer-lived sensitivity compared to the standard-of-care iodine-based contrast 
agent.  Many other AuNP formulations have since demonstrated good tumor 
accumulation and contrast,[265] including those with[267–270] and without[271,272] molecular 
targeting.  These highly-effective contrast agents could ultimately improve patient safety 
by allowing lower x-ray radiation doses. 
Photoacoustic imaging 
 In photoacoustic imaging, or PA, a material is irradiated with pulsed light and the 
absorbed energy is dissipated nonradiatively as heat.  While the laser is applied (i.e., 
“during” the pulses), local temperatures increase and the material undergoes 
thermoelastic expansion.  Between pulses, the temperature drops and the material 
contracts.  These repeated pressure changes generate acoustic waves, which can be 
detected as wideband ultrasonic emissions and eventually reconstructed into an image 
of this region.[273,274]  This imaging modality is commonly used to image endogenous 
photoabsorbers, which can be distinguished based on their spectral signals; for 
example, oxygenated and deoxygenated hemoglobin may be distinctly identified within 
tissues for comparisons of relative concentration.   
 Many gold particles can be excellent PA contrast agents due to their strong 
absorbance of light, though this absorbance depends strongly on particle size and 
shape.[274,275]  When imaging tissues, it is highly desirable to use contrast agents that 
absorb in the near-infrared (NIR) range (approximately 650-110 nm); light in this window 
has relatively low tissue absorption and therefore deeper penetration, which allows 
deeper imaging.[276]  This makes PA imaging one of the best and only ways to visualize 
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deep tissues in real time.  Furthermore, it does not require use of ionizing radiation, and 
its instrumentation is becoming progressively cheaper and more accessible.[277,278]  
These factors are likely to contribute to its increasing adoption in clinical settings. 
Photoluminescence and quenching 
 Gold nanoparticles can exhibit a property known as surface plasmon resonance 
(SPR).[11,279,280]  A particle’s electron cloud (i.e., conduction electrons) can collectively 
oscillate when excited at a specific frequency of light, resulting in strong absorbance at 
that wavelength.  This SPR absorbance peak is determined by the particle’s size, shape, 
and other properties; for example, it does not occur at all in very small nanoparticles (< 2 
nm).  In general, when gold particles aggregate (or otherwise closely associate), their 
absorbance spectrum will shift to reflect the SPR peak associated with the diameter of 
the larger composite; this has been utilized as a mechanism to detect local changes. [281–
283,280] 
 Gold is capable of strongly quenching the fluorescence of nearby 
materials.[284,285]  This phenomenon can also be utilized as a reporter of molecular 
conditions.  For example, fluorophores can be conjugated onto AuNP surfaces using 
environmentally-sensitive linkers; the dyes’ signals are quenched while bound to AuNPs, 
but they will emit detectably when they are cleaved from gold.[286–288]  When it is 
desirable to reduce the quenching effects of gold within particles, materials like silica can 
be installed as a buffer.[289,290]  However, gold’s quenching ability may also improve its 
utility in various applications, particularly those that rely on the nonradiative emission of 
absorbed energy (e.g., photoacoustic imaging and photothermal therapy). 
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1.4.2 Therapeutic applications 
Radiation therapy 
 Radiation therapy is one of the primary clinical paradigms for cancer treatment, 
indicated in approximately 50% of all cancer patients.[291]  In this process, ionizing 
radiation deposits energy into biological tissues and causes oxidation and fragmentation 
of DNA, proteins, and membranes.  This can occur directly when macromolecules 
absorb the applied radiation, but most damage (~70%) derives from their secondary 
reactions with ionized water or oxygen, i.e. reactive oxygen species. [292,293]  DNA 
damage,  especially in the form of double-strand breaks, are difficult for cells to repair 
and often result in cell cycle arrests and cell death.  However, incorrectly repaired DNA 
lesions might introduce new mutations, making it especially important that radiotherapy 
delivers effective killing doses to malignant cells while avoiding delivery to healthy 
tissues.[293] 
Radiation is typically applied as convergent beams of photons (gamma or x-
rays).  Another option, ion beam radiotherapy (e.g., protons), has gained increasing 
clinical prevalence due to its greater spatial precision; as ions pass through tissue, most 
of their energy is attenuated and deposited at a specific terminal distance termed the 
Bragg peak, which can be focused to the tumor’s position.[293,294]  Nevertheless, both 
photon and ion therapies risk significant exposure of healthy tissue, particularly along 
beam paths. 
Tumor specificity can be improved by applying radiosensitizers, which increase 
local energy deposition and/or vulnerability to damage.[295]  Gold nanoparticles function 
as potent radiosensitizers through a number of mechanisms.  As mentioned previously, 
gold’s high atomic number is associated with strong x-ray attenuation.  Upon photon 
28 
 
absorption, gold can eject secondary electrons, including A) inner-shell photoelectrons, 
with accompanying Auger electrons, at lower (keV) photon energies; and B) outer-shell 
Compton electrons at higher (MeV) photon energies (Figure 1.4).[295,296]  Notably, 
kilovoltage energies provide the greatest dose enhancement effect for gold over tissue, 
though megavoltage provides deeper tissue penetration and is the current clinical 
standard.[297]  AuNPs can also absorb energy through intermediary water- and oxygen-
derived radicals, and this mechanism likely contributes strongly to the radiosensitization 
effects observed in higher-energy photon therapy and in proton radiotherapy.[293,297]  In 
addition to emitting electrons, irradiated gold nanoparticles may increase generation of 
reactive oxygen species through catalytic reactions.[295]  Finally, AuNPs help confine the 
dose delivery area by increasing radiation attenuation within the tumor environment, 
reducing the fraction delivered to healthy tissues beyond and thereby improving safety 
margins.[293,296,298] 
 
Figure 1.4.  Mechanisms of photon attenuation and secondary emission by radiosensitizers.  Adapted by 
permission from Laprise-Pelletier et al.[296] 
Thermal therapy 
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 Hyperthermia is useful in several therapeutic applications, particularly in cancer, 
where localized heat can generate cellular damage and allow partial or complete tissue 
ablation.[299,300]  Cell death typically occurs at temperatures beyond 41-45 °C, through 
either apoptosis (mild heat) or necrosis (higher heat); high temperatures are typically 
pursued in bulk tissues to ensure sufficient temperature over spatial gradients. [300]  
Hyperthermia can also enhance the effectiveness of other therapeutic mechanisms.  For 
example, thermal stress induces protein damage that renders cells more susceptible to 
damage from radiotherapy and chemotherapy; hyperthermia can also increase tumor 
blood flow and thereby increase delivery of chemotherapeutic agents and 
radiosensitizing oxygen.[301–303]  Thermal destruction of cancer cells can also generate 
and disseminate tumor antigens, while local inflammation stimulates immune recruitment 
and activation, making hyperthermia a potential complement to immunotherapy.[300,304] 
Localized deep tissue heating can be induced non-invasively through application 
of ultrasound or long-wave electromagnetic radiation, which heat tissue directly.[305] 
However, nanoparticle-mediated heating techniques typically offer greater treatment 
precision both in uniformity and spatial resolution of tumor heating, thereby reducing 
damage to off-target tissues.[303,306]  As previously described, gold nanoparticles are 
capable of absorbing optical energy and converting it into heat;[307] photothermal therapy 
using gold nanoparticles and nanorods have been explored extensively since initial 
studies in 2003[308] and 2006[230], respectively.  Gold nanoparticles can also generate 
heat by absorbing radiofrequency radiation, though this process is more poorly 
understood and studied.[306,309] 
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CHAPTER 2: BIODEGRADABLE GOLD NANOCLUSTERS FROM PH-SENSITIVE 
ACETALATED DEXTRAN 
 
2.1 Abstract 
Gold is a highly useful nanomaterial for many clinical applications, but its poor 
biodegradability can impair long-term physiological clearance.  Large gold nanoparticles 
(20-200 nm), such as those required for long blood circulation times and appreciable 
tumor localization, often exhibit little to no dissolution and excretion.  This can be 
improved by incorporating small gold particles within a larger entity, but elimination may 
still be protracted due to incomplete dispersion of gold.  The present study describes a 
novel gold nanoparticle formulation capable of environmentally-triggered decomposition.  
Ultrasmall gold nanoparticles are coated with thiolated dextran, and hydrophobic acetal 
groups are installed through direct covalent modification of the dextran.  This 
hydrophobic exterior allows gold to be densely packed within ~150-nm polymeric 
micelles.  Upon exposure to an acidic environment, the acetal groups are removed and 
the gold nanoparticles become highly water-soluble, leading to destabilization of the 
micelle. Within 24 hours, the ultrasmall water-soluble gold particles are released from 
the micelle and readily dispersed.  Micelle degradation and gold nanoparticle dispersion 
was imaged in cultured macrophages, and micelle-treated mice displayed progressive 
physiological clearance of gold, with > 85% elimination from the liver over three months.  
These particles present a novel nanomaterial formulation and address a critical 
unresolved barrier for clinical translation of gold nanoparticles. 
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2.2 Introduction 
Gold nanoparticles (AuNPs) are among the most extensively studied 
nanoformulations, in part due to their easily manipulatable morphology and surface 
chemistry as well as their potential to be used in a variety of clinical applications. [1–3]  
Gold has attracted tremendous interest as a therapeutic agent – particularly in oncology 
– for applications including radiation sensitization[4–6] and photothermal therapy.[7–9]  It 
has also been explored in various biomedical imaging modalities, including computed 
tomography (CT),[10–12] photoacoustic imaging,[13,14] and surface-enhanced Raman 
scattering.[15]  Additionally, gold has been complexed with a range of other 
pharmaceuticals and imaging agents, as a scaffold for targeted delivery and multimodal 
activity.[12,16–18] 
The ability of AuNPs and other nanoparticles to target specific biological 
compartments is dependent on an optimized particle size (among other properties).  
Formulating AuNPs of approximately 20-200 nm helps confer long serum circulation 
times by avoiding rapid renal elimination.[19–21]  This also allows particles to preferentially 
localize to tumors via the enhanced permeability and retention effect (EPR), whereby 
circulating nanoparticles can extravasate through leaky tumor vasculature and persist 
due to poor lymphatic drainage.[22,23]  However, long-circulating AuNPs can exhibit 
impaired physiological clearance due to gold’s poor biodegradability.  Gold particles 
cannot be easily broken down, even within the lysosomal compartment’s highly acidic 
and hydrolytic environment, though a few processes may contribute to the slow 
degradation of gold over time (e.g., etching by thiols[24–26] or hydroxyl radicals[27,28]).  As a 
result, gold nanoparticles commonly persist in tissue for weeks to months.[29–31]  For 
example, in a landmark study by Sadauskas et al[32] in which 40-nm AuNPs were 
48 
 
administered intravenously to mice, it was found that only 9% of gold was eliminated 
from the liver over the course of six months.  Similarly, preclinical studies of 150-nm gold 
nanoshells showed no detectable reduction in total gold mass within the body, even at 
more than one year post-injection.[29]  The long-term persistence of gold nanoparticles 
represents a significant concern for clinical applications and regulatory approval.[33,34] 
In order to improve the clearance of AuNPs while maintaining favorable 
pharmacokinetics, one strategy is to package clusters of small AuNP cores within a 
larger biodegradable construct.  Such nanomaterials may be fabricated at an overall size 
that preserves favorable biodistribution, but the use of small gold particles can 
accelerate degradation and excretion.  This is because small hydrophilic AuNPs have 
the potential to be renally excreted[35–38] and retained particles may have improved 
deterioration due to their high surface-to-volume ratio.[30,39]  Several such AuNP clusters 
have been reported, using a variety of complexing materials (e.g., 
polyphosphazene,[40,41] polylysine and silica,[42] amphiphilic block copolymers containing 
poly(ethylene glycol) and polylactic acid[43,44] or polycaprolactone,[45] liposomes,[46,47] and 
oligonucleotides[48]). 
Recently, our group reported gold-loaded polymeric micelles consisting of 1.9-nm 
dodecanethiol-capped AuNPs encapsulated by poly(ethylene glycol)-block-poly(ε-
caprolactone) (PEG-PCL), with tunable micelle diameters of 30-150 nm.[49,50]  The use of 
hydrophobic AuNPs allowed facile particle synthesis through micelle self-assembly, and 
dense packing of substantial gold mass within the particle core.  These particles showed 
excellent tumor accumulation, biocompatibility, CT contrast, and radiosensitization.  The 
use of small AuNPs conferred significant improvements in bioelimination compared to 
large solid cores, with ~30% reduction in the liver from day 2 to day 7 post-injection.  In 
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later studies using 0.9-nm AuNPs, this was further improved to ~40% reduction in the 
first week, and up to 65% over three months.[51]  It was suspected that the residual 
biopersistence of gold resulted from incomplete dispersion of the hydrophobic particles. 
To that end, we have developed a novel gold nanomaterial that transitions from 
hydrophobic to hydrophilic under acidic conditions (Figure 2.1).  In particular, ultrasmall 
gold nanoparticles are coated with the pH-sensitive polymer, acetalated dextran.[52]  The 
resulting particles can be encapsulated within the hydrophobic core of an amphiphilic 
diblock copolymer, forming a tightly-packed polymeric micelle. Upon exposure to low pH 
environments (e.g., the cellular lysosomal compartment), the pendent acetal groups on 
the acetated dextran undergo hydrolysis, leading to disruption of the micelle and an 
increase in AuNP hydrophilicity.  These small, dispersed AuNPs have a greater capacity 
for degradation and excretion, allowing for faster and more extensive bioelimination.  
 
Figure 2.1. Schematic of AcetalDextran-AuNPs and AcetalDextran-AuNP-Micelles.  Ultrasmall gold particles 
are coated with a hydrophobic pH-sensitive polymer, acetalated dextran; upon exposure to low pH 
environments, this hydrophobic coating becomes hydrophilic.  Polymeric micelles encapsulating these 
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materials will be stable at standard physiological pH but will dissociate within the lysosome, allowing 
dispersion of soluble AuNPs. 
2.3 Results and Discussion 
A goal of this study was to produce dextran-coated gold nanoparticles that were 
smaller than the cutoff for renal clearance (estimated at 5-10 nm), which necessitated 
the production of even smaller AuNP cores (~2nm in diameter).  To produce these 
AuNPs, a protocol was adapted from Jadzinsky et al[53] using p-mercaptobenzoic acid as 
the capping ligand; this reaction could be scaled to produce monodisperse 1.7-nm gold 
particles at yields of several hundred milligrams (“pMBA-AuNPs”; Figure 2.2B).  These 
AuNPs were subsequently coated with a low-molecular-weight dextran (5 kDa) with a 
single terminal thiol group (Figure 2.2A). 
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Figure 2.2.  Synthesis of AcetalDextran-AuNPs.  (A) Dextran (5 kDa) was combined with 3,3'-
dithiobis(propanoic dihydrazide) to install a terminal thiol group.  (B) Ultrasmall hydrophilic gold 
nanoparticles (AuNPs) were synthesized using p-mercaptobenzoic acid (pMBA) as a capping ligand; 
particles had a mean diameter of 1.7 ± 0.5 nm (SEM).  Inset shows TEM image of dried particles.  (C) 
pMBA-AuNPs were coated with thiolated dextran via ligand exchange, yielding Dextran-AuNPs.  (D) 
Dextran-AuNPs were covalently modified with acetal groups, yielding AcetalDextran-AuNPs.  (E) 
Demonstration of water-soluble Dextran-AuNPs vs. chloroform-soluble AcetalDextran-AuNPs. 
Thiolated dextran was prepared by reductive amination of the terminal glucose 
moiety, which possesses a single transient aldehyde, with 3,3'-dithiobis(propanoic 
dihydrazide).  3,3'-dithiobis(propanoic dihydrazide) contains two terminal hydrazide 
groups and an internal disulfide.  Hydrazide was chosen as the aldehyde linking group, 
as opposed to a primary amine, because it is generally resistant to acidic hydrolysis, 
especially when it is further stabilized by reduction with cyanoborohydride. [54,55]  After 
conjugation of the dihydrazide with two dextran molecules, the disulfide was reduced 
with tris(2-carboxyethyl)phosphine (TCEP) to yield dextran-thiol, which was isolated by 
washing in 90% methanol.  Notably, disulfides are generally capable of binding gold 
surfaces without prior reduction;[56,57] however, we found that the dextran disulfide dimer 
could not be efficiently conjugated with gold, presumably due to steric occlusion. 
AuNPs were coated with dextran-thiol through simple ligand exchange in 
aqueous solution (“Dextran-AuNPs”; Figure 2.2C,E).  The successful addition of dextran 
was confirmed by analyzing the mass percentage of gold in purified particles: pMBA-
coated AuNPs were approximately 80% gold, but this dropped to 31% gold after the 
ligand exchange reaction, due to the larger size of dextran (Table 2.1).  Dextran-AuNPs 
were also examined by dynamic light scattering, and their average peak hydrodynamic 
diameter was 7.3 nm, suggesting the possibility of renal filtration.  
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 % Au [w/w]a Core diameterb Hydrodynamic    
diameterc 
Solubilityd pH sensitivitye 
pMBA-AuNPs 79.3% 1.7 ± 0.5 nm 5.0 nm 
PDI: 0.251 
Water No 
Dextran-AuNPs 31.0% 2.1 ± 0.5 nm 7.3 nm  
PDI: 0.246 
Water,  
DMSO 
No 
AcetalDextran-
AuNPs 
13.8% 2.1 ± 0.6 nm n/a Acetone, 
Toluene, 
Chloroform 
Yes 
AcetalDectran-
AuNP-Micelles 
11.4% 111.1 ± 38 nm 146.0 nm 
PDI: 0.156 
Water Yes 
 
Table 2.1.  Physiochemical parameters for AcetalDextran-AuNP-Micelles and precursor gold nanoparticles.  
aPercent gold mass measured by ICP-OES.  bCore diameters measured by transition electron microscopy, 
expressed as the average of 40-100 particle measurements, ± standard deviation.  cHydrodynamic 
diameters measured by dynamic light scattering, expressed as the mean intensity and polydispersity index 
averaged for three measurements (pMBA-AuNPs and Dextran-AuNPs, one batch; AcetalDextran-AuNP-
Micelles, six batches).  dSolubility is not comprehensive.  epH sensitivity refers to observed changes in 
particle solubility and sedimentation behavior after incubation at pH 5.0. 
After conjugation of AuNPs with dextran, the hydroxyl groups on the dextran 
were covalently modified with pendant acetal groups (Figure 2.2D,E) to increase the 
hydrophobicity of the particles and enable their encapsulation within micelles.  To 
append the acetal groups, Dextran-AuNPs were dissolved in dimethyl sulfoxide and then 
directly chemically reacted with 2-methoxypropene in the presence of the catalyst 
pyridinium-p-toluenesulfonate.  The resulting particles, “AcetalDextran-AuNPs” (or 
“ADAs”), were no longer soluble in water; instead, they could be dissolved in nonpolar 
organic solvents such as chloroform and toluene.  This, along with an additional 
decrease in particle gold mass percentage (Table 2.1), was indicative of a distinct 
compositional change from Dextran-AuNPs and strongly suggests the successful 
application of acetal groups. 
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The behavior of ADAs was characterized under acidic conditions to evaluate their 
ability to transition back to hydrophilic Dextran-AuNPs.  A range of aqueous buffers 
representing various physiological compartments were tested: PBS, pH 7.4, for blood; 
PBS, pH 6.8, for hypoxic tumors; and 0.3 M acetate buffer, pH 5.0, for lysosomes.  First, 
hydrophobic ADAs were suspended in each of these buffers, which initially formed a 
turbid suspension due to the insolubility of these particles (Figure 2.3A,B).  After several 
hours of mixing at 37 °C, particles at pH 7.4 and 6.8 appeared to remain unchanged.  
However, at pH 5.0, particles became fully water-soluble over the course of 12 hours, as 
evidenced by a dramatic increase in solution transmittance from cloudy (7.4 %T) to clear 
(60.7 %T).  To further confirm this behavior, we suspended AcetalDextran-AuNPs in 
serum at either pH 7.4 or pH 5.0 (Figure 2.3C).  Initially, particles could be precipitated 
by centrifugation, which indicated insolubility due to their hydrophobic acetal coating.  At 
later timepoints, particles at pH 5 lost this property and remained in solution even after 
high-speed centrifugation (16,000 x g, 10 min).  This shift in solubility is consistent with 
the expected hydrolysis of the acetal groups at low pH. 
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Figure 2.3.  pH-dependent solubility of particles incubated at pH 7.4 (PBS), pH 6.8 (PBS), or pH 5.0 (0.3M 
acetate).  (A) AcetalDextran-AuNPs (ADAs) were suspended in buffers (1.5 mg mL-1 by dry particle weight) 
and incubated at 37 °C under constant agitation for a total of 24 hours.  Representative images shown.  (B) 
Aliquots of AcetalDextran-AuNPs were removed and measured for absorbance at 750 nm; results 
expressed as percent transmittance, average of three measurements ± standard deviation.  (C,D) 
AcetalDextran-AuNPs or AcetalDextran-AuNP-Micelles (ADAMs) were suspended in serum (0.04 mg mL-1 
by Au, 1 mL) and incubated at 37 °C under constant agitation for a total of 24 hours.  Particles were 
centrifuged at 16,000 x g for 10 minutes; separate tubes were prepared for each timepoint.      
Next, the ADAs were encapsulated within polymeric micelles.  As noted, we have 
previously reported encapsulation of hydrophobic AuNPs using the biodegradable 
amphiphilic block copolymer PEG-PCL.[49–51]  Following a similar approach, 
“AcetalDextran-AuNP-Micelles” (or “ADAMs”) were formed by simple mixing of PEG-
PCL and gold particles in toluene, followed by emulsion in water and evaporation of 
toluene to drive micelle self-assembly (Figure 2.4A).  Micelles were isolated by 
centrifugal sedimentation to yield 146-nm water-soluble particles (Figure 2.4B).  Particle 
structure and size were confirmed by transition electron microscopy imaging (both 
standard- and Cryo-TEM) (Figure 2.4C).  Micelles were observed to be stable in 
phosphate-buffered saline (PBS) at 4 °C for at least one week, as evidenced by 
consistent hydrodynamic diameter and EM structure (Figure 2.4D). 
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Figure 2.4.  Formation of AcetalDextran-AuNP-Micelles.  (A) AcetalDextran-AuNPs and PEG-PCL were 
dissolved in toluene and then suspended in water to form an emulsion, driving self-assembly of 
AcetalDextran-AuNP-Micelles.  (B) Hydrodynamic diameter of micelles determined via dynamic light 
scattering.  The average peak hydrodynamic diameter was 146 nm (average of six batches).  (C) Electron 
microscopy imaging of micelles in water via Cryo-TEM and standard TEM.  (D) Hydrodynamic diameter of 
micelles in PBS at 4 °C, recorded immediately after dissolution and at 1 hour, 1 day, 3 days, 5 days, and 7 
days (average of three measurements, ± SEM).  At 7 days, the sample was diluted 10-fold in water to 
reduce salt concentration and then imaged by TEM (inset). 
To determine whether the ADAs could undergo a similar transition at pH 5 (i.e., 
going from hydrophobic to hydrophilic) after being encapsulated in micelles, ADAMs 
were dissolved in serum at either pH 7.4 or pH 5.0 (Figure 2.3D).  Although the micelles 
were fully soluble due to their outermost layer of PEG, their heavy gold cores meant they 
could be pelleted out of solution by high-speed centrifugation (16,000 x g, 10 min).  
When the micelles were mixed at 37 °C for 24 hours, those kept at pH 7.4 continued to 
146.0 nm 
PDI: 0.156 
 
56 
 
display the same behavior, and could be pelleted. In contrast, those exposed to acidic 
conditions could no longer be sedimented at these centrifugation speeds.  This suggests 
that the AuNPs no longer form a heavy gold core within the micelle and is consistent 
with our proposed model: the acidic environment leads to hydrolysis of the acetal 
groups, destabilization of the micelle core, and release of the Dextran-AuNPs. 
Importantly, this phenomenon can apparently occur without the need for degradation of 
the PEG-PCL, which is not expected to occur quickly under these conditions.[58] 
We next examined the behavior of ADAMs in biological systems.  Acetalated 
dextran has previously been proven to have toxicity comparable to that of poly(lactic-co-
glycolic acid), an FDA-approved material; safety was confirmed in particle form and for 
the isolated breakdown products of acetal hydrolysis (i.e., acetone and methanol). [52]  To 
confirm this behavior in the present formulation, ADAMs were incubated with an 
immortalized human liver cell line, HepG2, and a standard MTT assay was performed 
after 24 hours (Figure 2.5A).  Cell viability of ~95% was seen up to at least 10 µg mL-1 
gold, with no statistically significant decrease.  Even at very high concentrations (80 µg 
mL-1 Au), cells preserved more than 80% viability compared to media-only controls, 
suggesting good biocompatibility. 
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Figure 2.5.  AcetalDextran-AuNP-Micelles (ADAMs) in cell culture.  (A) ADAMs were incubated with HepG2 
human liver cells at various concentrations (expressed as µg mL-1 Au) for 24 hours, and cytotoxicity was 
assessed by MTT assay.  % Cell viability was calculated in relation to media-only controls; statistical 
comparison was performed using one-way ANOVA with post-hoc Tukey HSD test; *p < 0.05 relative to 
media controls.  (B,C) ADAMs or control micelles (C12-AuNP-Micelles) were incubated with RAW 264.7 
murine macrophages at 10 µg mL-1Au for 24 hours.  Cells were fixed and imaged by electron microscopy.  
Single cell shown for each condition, with expanded images on left. 
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The biodegradation of ADAMS was also assessed in cell culture.  As a control for 
these experiments, we prepared equivalent AuNP-loaded polymeric micelles that lacked 
pH sensitivity: 2-nm dodecanethiol-coated AuNPs (“C12-AuNPs”) formed into micelles 
using PEG-PCL (“C12-AuNP-Micelles”).[49]  Each micelle formulation was incubated with 
RAW 264.7 murine macrophages for 24 hours at 10 µg mL-1 gold; cells were then fixed, 
embedded, and sectioned for TEM analysis (Figure 2.5B,C).  AuNPs could be clearly 
visualized within unstained cells and were localized to vesicular compartments.  The pH-
sensitive ADAMs showed considerable breakdown of the spherical micelle structure and 
dispersion of individual AuNPs.  In contrast, control C12-AuNP-Micelles retained a 
distinctly spherical shape; although some separated AuNPs could be observed, the clear 
unidirectional distribution pattern strongly suggested that this was an artefact of the TEM 
tissue-sectioning process.  At this 24-hour timepoint, both micelle formulations had 
equivalent accumulation of gold within (or associated with) cells (ADAMs: 10.7 x10-9 µg 
per cell; C12-AuNP-Micelles: 9.84 x10-9 µg per cell).  
Finally, the pharmacokinetics of ADAMs was evaluated.  C57 black mice were 
injected intravenously with AcetalDex-AuNP-Micelles at a dose of 100 mg Au per kg 
body weight.  To determine the circulation time of micelles in the bloodstream, blood 
samples were drawn at various timepoints post-injection and analyzed for gold content.  
Micelles displayed long circulation, with a half-life of approximately 3.5 hours (Figure 
2.6A). 
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Figure 2.6.  In vivo pharmacokinetics and biodistribution of AcetalDextran-AuNP-Micelles.  Mice were 
injected intravenously with 100 mg Au per kg body weight, and samples were collected at various timepoints 
post-injection (n = 3 mice per timepoint, expressed as average ± SEM).  (A) Blood samples were analyzed 
by ICP-OES to determine gold content; curve-fitting performed using MATLAB software.  (B) Tissue and 
fluid samples were analyzed by ICP-OES to determine gold content (n = 3 mice per timepoint, expressed as 
average ± SEM.)  Statistical comparison was performed using one-way ANOVA with post-hoc Tukey HSD 
test; *p < 0.05 relative to measurement at 1 day.  (C) Urine was collected at 24 hours post-injection, diluted 
1:1 in pure water, and imaged by electron microscopy.  Electron-dense 2-nm particles are consistent with 
the appearance of Dextran-AuNPs. 
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A biodistribution analysis was performed by collecting organ samples at various 
timepoints for a total of twelve weeks and assessing tissue gold content using 
inductively-coupled plasma optical emission spectroscopy (ICP-OES) (Figure 2.6B).  
ADAMs displayed a tissue biodistribution pattern that is typical for nanoparticles of this 
size, with the majority of particles initially accumulating in the liver and spleen.  However, 
we observed a substantial drop in gold levels in these organs over time.  On average, 
liver gold decreased 86.1% over twelve weeks, while in the spleen it dropped 72% over 
that period.  Liver clearance was also more rapid; levels began to decrease appreciably 
after the first week, while spleen levels remained high for the first four weeks.  The 
mechanisms of micelle elimination were not examined in detail, but they likely involve 
endocytic uptake into cells, trafficking to lysosomes and other endosomal compartments, 
and exocytosis.  In the liver, hepatocytes periodically exocytose their lysosomal contents 
into bile, where it is carried to the digestive tract and excreted in feces.[59–61]  An 
appreciable amount of gold was detected in the feces, particularly at 1 day post-
injection.  This hepatobiliary excretion route may contribute to the faster elimination of 
gold from the liver vs. the spleen, where no equivalent system exists.   
Notably, by ICP-OES analysis, elemental gold could also be detected in the urine 
at 24 hours post-injection (%ID/g tissue: 4.5 ± 0.5).  We further explored this 
phenomenon by TEM imaging of urine samples (Figure 2.6C).  We observed electron-
dense 2-nm particles that were well-dispersed and consistent in appearance to pMBA-
AuNPs and Dextran-AuNPs.  These data confirm that intravenously injected 
AcetalDextran-AuNP-Micelles are capable of breaking down into renally excretable 
particles.  
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Throughout these studies, we examined mice for signs of drug-induced toxicity.  
Animals remained energetic and without visible signs of poor health (lethargy, noticeable 
changes in food intake, poor grooming, etc.).  Injected animals displayed an initial 
transient drop in body weight (10%), which may have been caused in part by the stress-
inducing effects of intravenous injection, repeated blood collection, and other handling 
procedures; this weight loss was resolved by day 4, and generally increased throughout 
the twelve-week study (Figure 2.7A).  Knowing the potential for high liver accumulation 
of particles, serum was collected from mice at 1, 3, and 7 days post-injection and 
analyzed for elevated liver enzymes: alanine transaminase (ALT), aspartate 
transaminase (AST), and alkaline phosphatase (ALP) (Figure 2.7B-D).  These levels 
were widely recorded to be within normal limits, with the single exception of increased 
AST at 1 day.  Notably, these assays involve colorimetric detection of enzymes;[62] at the 
1 day timepoint, serum contained a substantial volume of gold particles that imparted a 
noticeable brown hue, which may have impacted analysis.  Finally, tissue samples were 
harvested from the kidney, liver, spleen, and lung at various timepoints post-injection 
(Figure 2.7E).  Tissues were embedded with paraffin, stained with hematoxylin and 
eosin (H&E), and imaged by light microscopy.  Liver glycogen depletion was observed at 
Day 1, consistent with transient animal fasting; this correlates with the weight loss seen 
at Day 1, and as noted, may arise partially from general animal handling stress.  
Histological examination revealed no signs of acute or chronic pathology (apoptosis, 
immune cell infiltration, damage to tissue architecture, etc.), with the exception of mild 
spleen inflammation at Day 1, which diminished at 1 week and resolved by 3 months.[63] 
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Figure 2.7.  Safety profile of AcetalDextran-AuNP-Micelles after injection of 100 mg kg-1 Au.  A) Percent 
change in mouse body weight over time, normalized to pre-injection weight.  B-D) Serum measurements of 
alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase at various times post-
injection.  Gray shading represents standard clinical range for healthy mice.  n = 3 mice per group, ± SEM.  
E) Representative histological images of mouse organ tissues at various timepoints post-injection.  Tissues 
were paraffin-embedded and stained with H&E. 
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2.4 Conclusion 
Considering the extent of global research interest in gold nanoparticles and their 
therapeutic potential, it is important to address the lingering question of their 
physiological persistence.  The reported strategy seeks to improve clearance while still 
maintaining favorable aspects of gold particle design.  This has been achieved by 
utilizing a pH-sensitive polymer, acetalated dextran, which transitions from hydrophobic 
to hydrophilic in acidic conditions.  Acetalated dextran containing a single terminal thiol 
group has been installed onto ultrasmall AuNPs using newly-described synthetic 
strategies.  Clusters of these particles could then be encapsulated within polymeric 
micelles of favorable size, with high stability at pH 7.4.  However, both the hydrophobic 
AuNPs and their larger polymeric assemblies showed rapid degradation in acidic buffers 
(pH 5.0) and in macrophage cell culture.  Micelles were found to have good 
biocompatibility and serum pharmacokinetics; furthermore, they displayed progressive 
long-term clearance from accumulated tissues, including the liver and spleen.  
Collectively, these environmentally-responsive materials present an intriguing and 
effective strategy for the biodegradation of gold nanostructures. 
2.5 Experimental Section 
Materials:  Dextran (5 kDa, T5) was purchased from Phamacosmos.  3,3’-
dithiobis(propanoic dihydrazide) was purchased from Frontier Scientific.  Tris(2-
carboxyethyl(phosphine) (TCEP), gold(III) chloride trihydrate, tetraoctylammonium 
bromide, 1‐dodecanethiol, sodium borohydride, pyridinium-p-toluenesulfonate, and 2-
methoxypropene were purchased from Sigma Aldrich.  p-mercaptobenzoic acid (pMBA) 
was purchased from TCI America.  Sodium cyanoborohydride, triethylamine, fetal bovine 
serum (FBS), Dulbecco's Modified Eagle Medium (DMEM), Trypsin‐EDTA, and 
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penicillin–streptomycin solution were purchased from Thermo Fisher Scientific.  
Poly(ethylene glycol)4000‐b‐poly(ε‐caprolactone)3000 (PEG‐PCL) was purchased from 
Polymer Source.  PBS (1X, pH 7.4) was purchased from Quality Biological.  MTT assay 
kit was purchased from Roche Diagnostics GmbH.  Isoflurane was purchased from 
Akorn Animal Health. 
 
Synthesis of pMBA-AuNPs:  Hydrophilic gold nanoparticles coated in p-mercaptobenzoic 
acid (pMBA) were prepared using a protocol modified from Jadzinsky et al.[53]  Briefly, a 
stock solution of gold(III) chloride trihydrate (1 g mL-1) was first centrifuged for 30 
minutes at 16,000 x g to remove gold crystals, and then 400 µL was added to an acid-
washed flask and diluted in water (158 mL).  184 mL methanol was then added under 
vigorous stirring.  In parallel, pMBA was prepared as a 95 mM stock solution (726 mg in 
50 mL) containing 300 mM sodium hydroxide (595 mg), and then combined with the 
primary gold solution.  The resulting solution was allowed to equilibrate for 3-5 hours, 
until the color had changed from pale orange to nearly colorless.  Next, a freshly-
prepared 150 mM solution of sodium borohydride (159 mg in 28 mL water) was added to 
the reaction dropwise over the course of 15 minutes, resulting in a gradual color change 
to brown and then black over the course of 2 hours.  The solution continued stirring 
overnight.  Particles were then precipitated by adding methanol (467 mL) and an 
aqueous solution of sodium chloride (6.825 g in 47 mL) to the reaction mixture, then 
centrifuging at 3000 x g for 5 minutes. To wash particles, pellets were first suspended in 
70% methanol (v/v) and centrifuged again; next, pellets were dissolved in water and 
rinsed repeatedly using centrifugal filters (10,000 MWCO, Amicon).  Finally, particles 
were added to pre-weighed microcentrifuge tubes and then dried under centrifugal 
evaporation (Labconco). 
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Synthesis of thiolated dextran:  Thiolated dextran was prepared by reductive 
amination.[55]  Dextran (5 kDa; 14.163 g) and 3,3’-dithiobis(propanoic dihydrazide) (270 
mg) were dissolved in 300 mL acetate buffer (0.3 M, pH 5).  Sodium cyanoborohydride 
(approximately 2.6 g) was then added, and the reaction was allowed to stir for 24 hours.  
Next, a solution of TCEP (460 mg in 7 mL water) was brought to pH 5 using sodium 
hydroxide, then added to the primary reaction solution.  After 6 hours stirring, thiolated 
dextran was purified as follows.  First, the solvent was removed by lyophilization 
(Labconco) and the solid product was ground to a fine powder.  Next, solids were 
washed four times by suspension in 90% methanol (v/v) followed by centrifugation; 
between washes, pellets were mechanically disturbed either by agitating with a spatula 
(after first two washes) or by drying the pellet under vacuum and re-pulverized (after the 
third wash).  Finally, the product was dried under vacuum. 
 
Synthesis of Dextran-AuNPs:  pMBA-AuNPs were dissolved in aqueous solution at a 
concentration of approximately 2 mg mL-1 (by dry nanoparticle weight).  Thiolated 
dextran was added at approximately 10x molar equivalents relative to the pMBA ligand 
(1 part pMBA AuNPs : 85 parts Dext-SH, w:w; calculated by approximating AuNP mass 
percentage at 25% pMBA, and approximating molecular weight of thiolated dextran at 
5239 Da).  The reaction was stirred for 48 hours, and then purified by repeated washing 
using centrifugal filters (30,000 MWCO).  Finally, the resulting dextran-coated AuNPs 
were lyophilized. 
 
Synthesis of AcetalDextran-AuNPs:  Dextran-AuNPs were acetalated using a protocol 
adapted from Bachelder et al.[52]  A 20-mL long-necked air-free flask was flame-dried 
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under vacuum and then charged with nitrogen.  Meanwhile, Dextran-AuNPs (up to 500 
mg) were dissolved in 10 mL anhydrous DMSO, then combined with 16 mg pyridinium-p-
toluenesulfonate; this was transferred anaerobically to the reaction flask.  3.4 mL of 2-
methoxypropene was then injected into the same flask, which was allowed to stir for 3 
hours at room temperature under oxygen-free conditions.  The reaction was quenched 
by addition of 1 mL triethylamine.  To purify, the solution was diluted into 100 mL water, 
and approximately 10% volume was removed by rotary evaporation to ensure 
elimination of excess triethylamine.  The solution was then centrifuged at 3000 x g to 
collect precipitates.  Any solids that remained in the original reaction vessel or in the 
flask used for rotary evaporation were washed with water.  Finally, all precipitates were 
dissolved in acetone, combined, transferred into pre-weighed microcentrifuge tubes, 
then dried under centrifugal evaporation. 
 
Synthesis of AcetalDextran-AuNP-Micelles:  A solution was prepared containing 80 mg 
mL-1 of Acetal-Dextran-AuNPs (by dry particle weight) and 40 mg mL-1 of poly(ethylene 
glycol)-block-poly(ε-caprolactone) (PEG4000-PCL3000).  After thorough sonication, 100 µL 
of this solution was injected slowly into a glass scintillation vial containing 4 mL water 
under constant sonication (Branson, bath sonicator); sonication continued until a 
homogenous emulsion was formed.  Vials were lightly capped and placed under vacuum 
overnight to remove toluene, allowing formation of stable micelles.  Micelles were 
purified by centrifugation, first at 400 x g (10 minutes) to eliminate large precipitating 
aggregates and then at 16,000 x g (30 minutes) to sediment micelles.  This precipitate 
was then collected and further concentrated using centrifugal filters (100,000 MWCO).  
Particles were then stored at 4°C, typically after suspending in PBS (by adding 10x 
concentrate). 
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Synthesis of C12-AuNPs and C12-AuNP-Micelles:  Gold nanoparticles and gold-loaded 
polymeric micelles were synthesized as non-pH-sensitive experimental controls.  
Dodecanethiol-coated AuNPs (C12-AuNPs) were synthesized using the Brust method,[64] 
as adapted by Higbee-Dempsey et al.[65]  Dodecanethiol-coated AuNPs were then 
loaded into polymeric micelles using a protocol modified from by Al Zaki et al. [49,51]  PEG-
PCL (17 mg mL-1) and dodecanethiol AuNPs (17.5 mg mL-1 by dry particle weight) were 
dissolved in a total of 200 µL toluene.  This solution was sonicated and then injected into 
4 mL water to form a homogenous emulsion.  Purification then proceeded as described 
for AcetalDextran-AuNP-Micelles. 
 
Particle characterization:  Gold nanoparticles were characterized using a variety of 
physiochemical methods.  Particles were imaged by electron microscopy using a Tecnai 
T12 microscope to determine gold diameter and overall particle morphology; size 
analysis was performed using ImageJ software.  Hydrodynamic diameter and zeta 
potential were measured using a Zetasizer Nano ZS (Malvern Panalytical); data are 
generally expressed as the average of triplicate measurements of one synthetic batch; 
while data for AcetalDextran-AuNP-Micelles represent an average of six batches.  Gold 
concentration was determined using inductively-coupled plasma optical emission 
spectroscopy (ICP-OES) on a Spectro Genesis.  To prepare samples for ICP-OES, 
solutions were placed in borosilicate glass tubes containing up to 1 mL of freshly-
prepared aqua regia (a 1:3 mixture of nitric acid and hydrochloric acid; e.g., 250 µL 
HNO3 and 750 µL HCl); tubes were lightly sealed with PFTE-lined caps, allowed to stand 
for at least 20 minutes to ensure complete dissolution of gold, and then diluted in water 
up to a known volume. 
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Evaluation of acid-responsiveness:  AcetalDextran-AuNPs were first dissolved in 
acetone and then diluted into buffered solutions at one of three pHs: pH 7.4 (PBS); pH 
6.4 (PBS, titrated to 6.8 using 1 M sodium hydroxide); or pH 5.0 (acetate buffer, 0.3 M).  
All solutions consisted of 1.5 mg mL-1 AuNPs (by dry particle weight) and 2% acetone 
(v/v).  Solutions were placed at 37 °C and agitated vigorously using an orbital shaker.  
Every 1.5 hours, triplicate aliquots were removed and analyzed.  Absorbance was 
measured at 750 nm (Tecan) to determine solution turbidity, as calculated using the 
following equation: 
 
% Transmittance =  antilog (2 –  absorbance)     (1) 
 
Samples were then diluted to a concentration of 1 mg mL-1 and photographed. 
In separate experiments, AcetalDextran-AuNPs and AcetalDextran-AuNP-
Micelles were examined in serum.  First, fetal bovine serum was sterilely titrated to pH 
5.0 using hydrochloric acid; this serum and unmodified serum were equilibrated at 4 °C 
overnight, and then centrifuged at 3000 x g for 30 minutes to remove any aggregated 
proteins.  Gold particles were then sterilely dissolved in both serums at a concentration 
of 0.04 mg mL-1 by Au, and divided into two 1.5-mL sterile microfuge tubes per 
experimental group (1 mL each).  One set of tubes were immediately centrifuged at 
16,000 x g for 10 minutes, and pellets were photographed; the other set of tubes were 
incubated at 37°C for 24 hours under constant agitation, then similarly centrifuged and 
photographed. 
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Cell culture:  RAW 264.7 and HepG2 cells were acquired from ATCC.  Cells were grown 
at 37°C with 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum and 1% pen strep.  Cell passage numbers were kept low (< 10) 
to prevent genetic drift; during passage, RAW 264.7 cells were dissociated using cell 
scrapers, while HepG2 cells were dissociated with trypsin-EDTA. 
 
Determination of cell viability:  HepG2 human liver cancer cells were examined by MTT 
assay to determine cell viability.  Cells were first seeded in a 96-well plate (1 x 105 cells 
per well).  The following day, media was carefully removed by pipette and replaced with 
100 µL fresh media containing AcetalDextran-AuNP-Micelles at concentrations ranging 
from 0 to 80 µg mL-1 (by Au concentration).  Cells were incubated for 24 hours, after 
which the media was removed and wells were washed with 200 µL PBS.  Finally, cells 
were given fresh media containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT).  The MTT assay then proceeded according to the manufacturer’s 
instructions.  Cell viability was normalized to untreated control cells, and all conditions 
were performed in triplicate wells. 
 
Imaging cell uptake:  To examine cellular uptake of AcetalDextran-AuNP-micelles, 
particles were incubated with RAW 264.7 mouse macrophages.  Cells were first seeded 
in 6-well plates (2 x 106 cells per well, quadruplicate conditions).  The following day, 
media was carefully removed by pipette and replaced with 1 mL fresh media containing 
micelles at a concentration of 10 µg Au per mL.  In parallel control experiments, cells 
were treated with 10 µg/mL C12-AuNP-Micelles.  After 24-hours incubation, media was 
carefully collected by pipette and set aside; cells were then gently washed with 1 mL 
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PBS, which was also collected.  An additional 1 mL PBS was then added, and adherent 
cells were gently harvested using cell scrapers.   
Cells were then examined using several techniques.  In one set of experiments, 
cells (3 wells each) were counted using a hemocytometer, transferred into pre-weighed 
centrifuge tubes, weighed again, and lyophilized until dry.  Dry tubes were weighed a 
final time, and then solids were dissolved in 1 mL aqua regia and processed for ICP-
OES analysis as described.  Tube weights were used to calculate exact number and 
mass of cells. 
In another set of experiments, washed cells (1 well each) were centrifuged at 500 
x g for 5 minutes, and cell pellets were gently resuspended in 100 µL of fixative solution 
containing 2% glutaraldehyde and 2% paraformaldehyde (w/v).  Cells were then 
prepared for EM imaging by the University of Pennsylvania Electron Microscopy 
Resource Lab, and imaged on a JEOL 1010 microscope. 
 
Animal welfare statement:  Female C57BL/6 mice (6-8 weeks old) were obtained from 
Charles River.  All animals were housed and maintained according to procedures 
approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee.  Mice were fed nutritionally standard chow containing fenbendazole, with 
free access to food and water. 
 
Biodistribution and safety of AcetalDextran-AuNP-Micelles:  Mice were intravenously 
injected with AcetalDextran-AuN-Micelles at a concentration of 100 mg Au per kg body 
weight (n = 18 mice total).  Blood samples were then collected from the opposite tail vein 
at the following timepoints: 2 hours, 6 hours, 24 hours, and 72 hours.  At each timepoint, 
approximately 10-25 µL were removed from each of three mice, which were randomized 
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such that every mouse underwent no more than 3 blood draws in total.  Whole blood 
samples were then analyzed by ICP-OES as described, by digestion in 1 mL aqua regia 
for a minimum of one hour.  Half-life of gold in blood samples was determined by fitting a 
double exponential decay curve to the data using MATLAB software (Mathworks). 
Mice were then sacrificed at various timepoints post-injection: 1 day, 3 days, 1 
week, 2 weeks, 4 weeks, and 12 weeks (n = 3 mice per group).  Prior to sacrifice, urine 
and feces samples (12-130 µL and 18-75 mg, respectively) were collected from lightly-
scruffed mice.  Mice were then anesthetized with isoflurane (3%, 1.5 L min-1 O2), and a 
minimum of 500 µL blood was collected via cardiac puncture.  Mice were euthanized by 
cervical dislocation, and the following organs were harvested: brain, heart, kidney, liver, 
lung, muscle, skin, and spleen.  Organs were lightly rinsed in PBS immediately following 
extraction.   
At days 1, 3, and 7, cardiac blood was centrifuged to collect serum and then 
analyzed for liver enzymes by the Penn Vet Clinical Pathology Diagnostic Lab.  At day 1, 
urine (n = 1 mouse) was examined by TEM imaging; 5 µL of urine was diluted 1:1 with 
water and placed onto a TEM grid for 3 minutes, then grids were lightly blotted, allowed 
to air-dry, and imaged using a Tecnai T12 microscope.   
Feces, urine, and organ samples were analyzed by ICP-OES as described, by 
digestion in 1 mL aqua regia for a minimum of 12 hours.  Several tissue samples were 
reserved for histological evaluation at 1 day, 1 week, and 3 months: kidney (n = 3 per 
timepoint), liver (n = 3), spleen (n = 3), and lung (n = 1).  Sections of these tissues were 
fixed in formalin; paraffin embedding was performed by the Penn Center for 
Musculoskeletal Disorders Histology Core, while sectioning and staining was performed 
by the Penn Vet Comparative Histology Core.  All samples were then imaged using an 
EVOS light microscope and were examined for signs of pathology.  At day 1, separate 
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liver tissue sections were also preserved for examination of ultrastructure by electron 
microscopy.  These were suspended in 100 µL of fixative solution containing 2% 
glutaraldehyde and 2% paraformaldehyde (w/v), and prepared for EM imaging by the 
University of Pennsylvania Electron Microscopy Resource Lab; imaging was performed 
on a JEOL 1010 microscope. 
 
Statistical analysis:  Statistical analysis was performed using one-way ANOVA with post-
hoc Tukey HSD test, using Astatsa online software (http://astatsa.com). 
2.6 References 
[1] Y.-C. Yeh, B. Creran, V. M. Rotello, Nanoscale 2012, 4, 1871–1880. 
[2] S. Jain, D. G. Hirst, J. M. O’Sullivan, Br J Radiol 2012, 85, 101–113. 
[3] N. Elahi, M. Kamali, M. H. Baghersad, Talanta 2018, 184, 537–556. 
[4] D. R. Cooper, D. Bekah, J. L. Nadeau, Front. Chem. 2014, 2. 
[5] K. Haume, S. Rosa, S. Grellet, M. A. Śmiałek, K. T. Butterworth, A. V. Solov’yov, K. M. Prise, J. 
Golding, N. J. Mason, Cancer Nanotechnol 2016, 7, DOI 10.1186/s12645-016-0021-x. 
[6] M. Laprise‐Pelletier, T. Simão, M.-A. Fortin, Advanced Healthcare Materials 2018, 7, 1701460. 
[7] N. S. Abadeer, C. J. Murphy, J. Phys. Chem. C 2016, 120, 4691–4716. 
[8] R. S. Riley, E. S. Day, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2017, 
9, e1449. 
[9] J. B. Vines, J.-H. Yoon, N.-E. Ryu, D.-J. Lim, H. Park, Front. Chem. 2019, 7, DOI 
10.3389/fchem.2019.00167. 
[10] D. Xi, S. Dong, X. Meng, Q. Lu, L. Meng, J. Ye, RSC Adv. 2012, 2, 12515–12524. 
[11] T. Dreifuss, E. Barnoy, M. Motiei, R. Popovtzer, in Design and Applications of Nanoparticles in 
Biomedical Imaging (Eds.: J.W.M. Bulte, M.M.J. Modo), Springer International Publishing, Cham, 
2017, pp. 403–427. 
[12] M. M. Mahan, A. L. Doiron, J. Nanomater. 2018, 2018, 5837276. 
[13] W. Li, X. Chen, Nanomedicine 2015, 10, 299–320. 
[14] Q. Fu, R. Zhu, J. Song, H. Yang, X. Chen, Advanced Materials 2019, 31, 1805875. 
73 
 
[15] Y. Li, Q. Wei, F. Ma, X. Li, F. Liu, M. Zhou, Acta Pharmaceutica Sinica B 2018, 8, 349–359. 
[16] I. Fratoddi, I. Venditti, C. Cametti, M. V. Russo, J. Mater. Chem. B 2014, 2, 4204–4220. 
[17] P. R. Chandran, R. T. Thomas, in Nanotechnology Applications for Tissue Engineering (Eds.: S. 
Thomas, Y. Grohens, N. Ninan), William Andrew Publishing, Oxford, 2015, pp. 221–237. 
[18] F.Y. Kong, J.W. Zhang, R.F. Li, Z.X. Wang, W.J. Wang, W. Wang, Molecules 2017, 22, 1445. 
[19] J. Liu, M. Yu, C. Zhou, J. Zheng, Materials Today 2013, 16, 477–486. 
[20] H. H. Gustafson, D. Holt-Casper, D. W. Grainger, H. Ghandehari, Nano Today 2015, 10, 487–510. 
[21] A. Albanese, P. S. Tang, W. C. W. Chan, Annu. Rev. Biomed. Eng. 2012, 14, 1–16. 
[22] Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387–6392. 
[23] R. K. Jain, T. Stylianopoulos, Nature Reviews Clinical Oncology 2010, 7, 653–664. 
[24] T. G. Schaaff, R. L. Whetten, J. Phys. Chem. B 1999, 103, 9394–9396. 
[25] J. P. Wilcoxon, P. Provencio, J. Phys. Chem. B 2003, 107, 12949–12957. 
[26] Y. Shichibu, Y. Negishi, H. Tsunoyama, M. Kanehara, T. Teranishi, T. Tsukuda, Small 2007, 3, 835–
839. 
[27] A. M. Nowicka, U. Hasse, M. Hermes, F. Scholz, Angewandte Chemie International Edition 2010, 49, 
1061–1063. 
[28] T.-H. Chen, C.-C. Nieh, Y.-C. Shih, C.-Y. Ke, W.-L. Tseng, RSC Advances 2015, 5, 45158–45164. 
[29] S. C. Gad, K. L. Sharp, C. Montgomery, J. D. Payne, G. P. Goodrich, Int J Toxicol 2012, 31, 584–594. 
[30] J. Kolosnjaj-Tabi, Y. Javed, L. Lartigue, J. Volatron, D. Elgrabli, I. Marangon, G. Pugliese, B. Caron, 
A. Figuerola, N. Luciani, et al., ACS Nano 2015, 9, 7925–7939. 
[31] J. Kolosnjaj-Tabi, J. Volatron, F. Gazeau, in Design and Applications of Nanoparticles in Biomedical 
Imaging (Eds.: J.W.M. Bulte, M.M.J. Modo), Springer International Publishing, Cham, 2017, pp. 9–41. 
[32] E. Sadauskas, G. Danscher, M. Stoltenberg, U. Vogel, A. Larsen, H. Wallin, Nanomedicine 2009, 5, 
162–169. 
[33] H. A. Havel, AAPS J 2016, 18, 1351–1353. 
[34] A. Radomska, J. Leszczyszyn, M. W. Radomski, Adv Clin Exp Med 2016, 25, 151–162. 
[35] J. F. Hainfeld, D. N. Slatkin, T. M. Focella, H. M. Smilowitz, BJR 2006, 79, 248–253. 
[36] W.-S. Cho, M. Cho, J. Jeong, M. Choi, B. S. Han, H.-S. Shin, J. Hong, B. H. Chung, J. Jeong, M.-H. 
Cho, Toxicology and Applied Pharmacology 2010, 245, 116–123. 
74 
 
[37] C. Zhou, M. Long, Y. Qin, X. Sun, J. Zheng, Angewandte Chemie International Edition 2011, 50, 
3168–3172. 
[38] F. Naz, V. Koul, A. Srivastava, Y. K. Gupta, A. K. Dinda, Journal of Drug Targeting 2016, 24, 720–
729. 
[39] U. Carlander, K. Midander, Y. S. Hedberg, G. Johanson, M. Bottai, H. L. Karlsson, ACS Appl. Bio 
Mater. 2019, 2, 1006–1016. 
[40] R. Cheheltani, R. M. Ezzibdeh, P. Chhour, K. Pulaparthi, J. Kim, M. Jurcova, J. C. Hsu, C. Blundell, H. 
I. Litt, V. A. Ferrari, et al., Biomaterials 2016, 102, 87–97. 
[41] M. Bouché, M. Pühringer, A. Iturmendi, A. Amirshaghaghi, A. Tsourkas, I. Teasdale, D. P. Cormode, 
ACS Appl. Mater. Interfaces 2019, 11, 28648–28656. 
[42] D. Cassano, M. Summa, S. Pocoví‐Martínez, A.-K. Mapanao, T. Catelani, R. Bertorelli, V. Voliani, 
Particle & Particle Systems Characterization 2019, 36, 1800464. 
[43] J. M. Tam, J. O. Tam, A. Murthy, D. R. Ingram, L. L. Ma, K. Travis, K. P. Johnston, K. V. Sokolov, 
ACS Nano 2010, 4, 2178–2184. 
[44] J. M. Tam, A. K. Murthy, D. R. Ingram, R. Nguyen, K. V. Sokolov, K. P. Johnston, Langmuir 2010, 26, 
8988-99. 
[45] P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang, X. Sun, M. Aronova, G. Niu, et al., 
Angew Chem Int Ed Engl 2013, 52, 13958–13964. 
[46] T. S. Troutman, J. K. Barton, M. Romanowski, Advanced Materials 2008, 20, 2604–2608. 
[47] A. K. Rengan, A. B. Bukhari, A. Pradhan, R. Malhotra, R. Banerjee, R. Srivastava, A. De, Nano Lett. 
2015, 15, 842–848. 
[48] L. Y. T. Chou, K. Zagorovsky, W. C. W. Chan, Nature Nanotechnology 2014, 9, 148–155. 
[49] A. Al Zaki, D. Joh, Z. Cheng, A. L. B. De Barros, G. Kao, J. Dorsey, A. Tsourkas, ACS Nano 2014, 8, 
104–112. 
[50] C. McQuade, A. A. Zaki, Y. Desai, M. Vido, T. Sakhuja, Z. Cheng, R. J. Hickey, D. Joh, S.-J. Park, G. 
Kao, et al., Small 2015, 11, 834–843. 
[51] A. A. Zaki, J. Z. Hui, E. Higbee, A. Tsourkas, J Biomed Nanotechnol 2015, 11, 1836–1846. 
[52] E. M. Bachelder, T. T. Beaudette, K. E. Broaders, J. Dashe, J. M. J. Fréchet, J. Am. Chem. Soc. 
2008, 130, 10494–10495. 
75 
 
[53] P. D. Jadzinsky, G. Calero, C. J. Ackerson, D. A. Bushnell, R. D. Kornberg, Science 2007, 318, 430–
433. 
[54] J. P. O’Donnell, Drug Metabolism Reviews 1982, 13, 123-59. 
[55] G. Hermanson, Bioconjugate Techniques, Elsevier, 1996. 
[56] H. Grönbeck, A. Curioni, W. Andreoni, J. Am. Chem. Soc. 2000, 122, 3839–3842. 
[57] J. C. Love, L. A. Estroff, J. K. Kriebel, R. G. Nuzzo, G. M. Whitesides, Chem. Rev. 2005, 105, 1103–
1170. 
[58] A. R. Hernández, O. C. Contreras, J. C. Acevedo, L. G. N. Moreno, American Journal of Polymer 
Science 2013, 3, 70–75. 
[59] G. Renaud, R. L. Hamilton, R. J. Havel, Hepatology 1989, 9, 380–392. 
[60] Y.-N. Zhang, W. Poon, A. J. Tavares, I. D. McGilvray, W. C. W. Chan, Journal of Controlled Release 
2016, 240, 332–348. 
[61] H. Wang, C. A. Thorling, X. Liang, K. R. Bridle, J. E. Grice, Y. Zhu, D. H. G. Crawford, Z. P. Xu, X. Liu, 
M. S. Roberts, J. Mater. Chem. B 2015, 3, 939–958. 
[62] X.J. Huang, Y.-K. Choi, H.-S. Im, O. Yarimaga, E. Yoon, H.-S. Kim, Sensors (Basel) 2006, 6, 756–
782. 
[63] K. E. Ibrahim, M. G. Al-Mutary, A. O. Bakhiet, H. A. Khan, Molecules 2018, 23, E1848. 
[64] M. Brust, M. Walker, D. Bethell, D. J. Schiffrin, R. Whyman, Journal of the Chemical Society, 
Chemical Communications 1994, 0, 801–802. 
[65] E. Higbee-Dempsey, A. Amirshaghaghi, M. J. Case, J. Miller, T. M. Busch, A. Tsourkas, Advanced 
Therapeutics 2019, 0, 1900088.  
76 
 
CHAPTER 3: INDOCYANINE GREEN-COATED GOLD NANOCLUSTERS FOR 
PHOTOACOUSTIC IMAGING AND PHOTOTHERMAL THERAPY 
 
3.1 Abstract 
Traditional oncology treatment modalities are often associated with a poor 
therapeutic index.  This has driven the development of new targeted treatment 
modalities, including several based on the conversion of optical light into heat energy 
(photothermal therapy, PTT) and sound waves (photoacoustic imaging, PA) that can be 
applied locally.  These approaches are especially effective when combined with 
photoactive nanoparticles that preferentially accumulate in tissues of interest and 
thereby further increase spatiotemporal resolution.  In this study, two clinically-used 
materials that have proven effective in both PTT and PA – indocyanine green and gold 
nanoparticles – were combined into a single nanoformulation.  These particles, “ICG-
AuNP clusters”, incorporated high concentrations of both moieties without the need for 
additional stabilizing or solubilizing reagents.  The clusters demonstrated high 
theranostic efficacy both in vitro and in vivo, compared with ICG alone.  Specifically, in 
an orthotopic mouse model of triple-negative breast cancer, ICG-AuNP clusters could be 
injected intravenously, imaged in the tumor by PA, and then combined with near-infrared 
laser irradiation to successfully thermally ablate tumors and prolong animal survival.  
Altogether, this novel nanomaterial demonstrates excellent therapeutic potential for 
integrated treatment and imaging. 
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3.2 Introduction 
Radiation therapy has long represented a paradigm in the treatment of cancer, 
with multiple advantages including efficacy against many tumor types and localized 
delivery.[1–3]  Traditional radiation therapy involves the use of high-energy ionizing 
radiation – typically photons or charged particles – that relies on the inherent absorptive 
properties of that tissue to deposit energy.  However, this broad cytotoxicity may 
contribute to inadvertent damage of adjacent healthy cells, particularly tissue in the path 
of radiation.  Ionizing radiation is also a critical component of computed tomography (CT) 
and other imaging modalities used to clinically visualize malignant tissue; though dosage 
is usually low, these procedures may themselves pose risks to normal biological tissue. [4] 
A new class of therapies and diagnostics have emerged that harness lower-
energy forms of radiation, including infrared and visible light.[5–9]  While less harmful to 
tissues on their own, these can be applied in combination with localized exogenous 
agents that mediate and enhance tissue interactions, thereby achieving site-specific 
efficacy with reduced damage to off-target tissues.  In particular, near infrared light (NIR, 
650 – 1350 nm) is a highly attractive radiation source primarily due to its relatively deep 
tissue penetration – up to several centimeters – compared to lower-wavelength light.[10,11]  
NIR photomedicine has been broadly applied in cancer treatment and imaging through 
numerous modalities,[8] including: photodynamic therapy, or PDT (light excites a 
photoactive agent to a triplet excited state, which then directly or indirectly generates 
free radicals and/or reactive oxygen species); photothermal therapy, or PTT (absorbed 
energy is emitted as vibrational energy – i.e., heat); fluorescence imaging (energy is 
emitted radiatively as a photon); and photoacoustic imaging (energy is emitted as heat, 
which generates a detectable acoustic wave).  Photoacoustic imaging has become 
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increasingly popular due to its deep signal penetration (≤ 5-6 cm), high resolution (≥ 
5µm), and decreasing instrument costs.[12–16]  Furthermore, because the molecular 
contrast agents for photoacoustic imaging are optimized for non-radiative emission, 
many of these same materials can be utilized for photothermal therapy, allowing dual 
clinical functionality.[9]  PTT has a potential advantage over photodynamic therapy, in 
that it does not require the presence of oxygen, the concentration of which may be 
limited in large solid tumors.[17] 
To take advantage of photomedicine’s increased safety margin, it is necessary 
for a photoactive moiety to be localized to the tumor tissue; however, this can be difficult 
to achieve for many traditional small molecule agents.  Nanoscale formulations may be 
particularly useful for overcoming these targeting limitations.  Due to their unique 
physical, chemical, and biological properties, nanoparticles can: 1) deliver high volumes 
of cargo to regions of interest, 2) maintain cargo in a desired site at an optimal time 
period for clinical intervention, and 3) reduce cargo accumulation in off-target sites.[18]  
An excellent candidate for nanoformulation – with great potential in both PTT and 
photoacoustic imaging – is indocyanine green (ICG), which at present is the only FDA-
approved near-infrared dye.[19,20]  As a small molecule, ICG’s utility is limited because of 
its instability in aqueous solution – especially when combined with light, heat, or salts – 
as well as its rapid clearance from the bloodstream, which can prevent the high, 
localized concentrations desirable for intervention in tumors.  While these shortcomings 
would likely improve in a nanoformulation, ICG can be difficult to load in large quantities 
due to its amphiphilicity and lack of easily-modifiable chemical groups. 
Recently, we reported several novel fluorophore-based nanoparticle structures 
wherein a dye – ICG, protoporphyrin IX, or chlorin e6 – was combined with only one 
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other common component: superparamagnetic iron oxide nanoparticles (SPIOs). [21–23]  In 
these three structures, the amphiphilic dye molecules were utilized as an outer coating 
to stabilize clusters of hydrophobic SPIO particles, thereby thermodynamically driving 
ICG to remain bound in large concentrations.  The ICG-SPIO nanoclusters were 
successfully employed in image-guided surgery based on photoacoustic imaging (of 
ICG) and pre-surgical MR imaging (of SPIOs).  However, in all of these studies, SPIOs 
were utilized for MR imaging and as a scaffold for the amphiphilic dye, but were not 
designed to contribute directly to tumor therapy. 
With this in mind, we sought to further expand the utility of ICG clusters by 
creating an inherently theranostic nanoformulation for combined photoacoustic imaging 
and photothermal therapy, whereby both materials were capable of contributing to each 
modality.  For this, we selected another material that has been proven dually efficacious 
in both photothermal therapy and photoacoustic imaging: gold nanoparticles 
(AuNPs).[5,13,16,24,25]  Several groups have reported physiological studies of particles 
combining ICG and gold, but these particles have several key drawbacks.  For example, 
they incorporated significant quantities of inert binding materials (serum albumin,[26,27] 
silica,[28–31] poly(styrene-alt-maleic anhydride),[32] polyethyleneimine,[32,33] chitosan[27,34], 
and poly(lactic-co-glycolic acid[27]), thereby reducing the per-particle loading of 
functionally active ICG and Au.  Also, almost all of these studies used large gold 
particles (15 - 150 nm), which are well-known to display protracted physiological 
elimination.[35,36]  We have previously demonstrated the utility of using 2-nm 
dodecanethiol-coated AuNPs in micellar nanoformulations: they can be densely packed 
to provide high Au payloads with extremely low non-gold mass, while their small 
individual size facilitates long-term physiological clearance.[37,38]  In the current study, 
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ICG was successfully formulated at high concentrations into a stable nanoformulation 
with ultrasmall hydrophobic AuNPs.  These dual-component nanoclusters show 
favorable long-term biological clearance, as well as great promise for both photoacoustic 
imaging and photothermal therapy. 
3.3 Results and Discussion 
Preparation and Characterization of ICG-AuNP Clusters 
ICG and gold were formulated into a stable, water-soluble nanomaterial using a 
rapid and facile nanoemulsion methodology (Figure 3.1A).  We first synthesized 
ultrasmall hydrophobic gold nanoparticles (AuNPs) consisting of 2-nm gold cores coated 
with dodecanethiol (Figure 3.2A,B).[39]  Small clusters of AuNPs were then solubilized by 
using ICG as an amphiphilic coating.  To prepare these clusters, ICG was combined with 
AuNPs in organic solvent and then emulsified into water, driving self-assembly of the two 
materials into discrete spheroids (Figure 3.1B,C).  TEM images confirmed the expected 
clusters of ultrasmall AuNPs.  ICG is not visible in such images, preventing observation 
of ICG location; however, we consistently observed that clusters in close proximity 
display a thick “halo” that could be indicative of ICG presence on the surface (Figure 
3.1B, inset).  Clusters exhibited a favorable hydrodynamic size and narrow size 
distribution (61.22 ± 2.63 nm); this diameter stayed constant over time, suggesting that 
clusters remain stable in water without detectable aggregation (Figure 3.1D).  Due to the 
inclusion of ICG, clusters were found to be highly negatively-charged, with a zeta 
potential of –26.1 ± 12.6.   
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Figure 3.1.  (A) Schematic of ICG-AuNP clusters, consisting of 2-nm dodecanethiol-coated gold 
nanoparticles (AuNP) packed within the core and coated with a dense outer layer of indocyanine green 
(ICG).  (B) TEM images of clusters.  (C) DLS of clusters in water showing hydrodynamic diameter; the 
average hydrodynamic diameter was 61.22 ± 2.63 nm (standard deviation, n = 2 particle batches).  (D) Peak 
hydrodynamic diameter of clusters in solution (water, 4°C, dark) over the course of one week.  n = 3 
measurements, ± SEM.  (E) Absorbance (solid lines) and fluorescence (dashed lines) of clusters dissolved 
in serum vs. equivalent concentrations of free ICG (3 µg mL-1 ICG) or dodecanethiol AuNPs (20 µg mL-1 Au).  
Cluster absorbance maximum = 803 nm; fluorescence maximum = 820 nm. 
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Figure 3.2.  Dodecanethiol-coated gold nanoparticles (AuNPs).  (A) Electron micrograph of AuNPs (scale 
bar = 20 nm).  (B) Size distribution of AuNPs, determined by measuring the diameter of 100 individual 
particles.  The average diameter was 2.42 ± 0.5 nm (standard deviation).  (C) Electron micrograph of 
polymer-AuNP clusters (scale bar = 50 nm).  (D) Size distribution of polymer-AuNP clusters, measured by 
dynamic light scattering (± standard deviation, n = 3 measurements). 
We then sought to further understand the interaction between ICG and AuNPs 
within the cluster, and assess whether ICG might displace dodecanethiol on the AuNP 
surface.  Knowing that ICG, but not dodecanethiol, is soluble in dimethylformamide, we 
dissolved ICG-AuNP clusters in this medium and centrifuged to separate out any 
insoluble material.  The precipitate was found to be soluble only in highly nonpolar 
solvents such as toluene and the absorbance spectra matched that of AuNPs, but not 
ICG.  In contrast, the absorbance spectra of the supernatant matched that of ICG, but 
83 
 
not AuNPs.  There was no mixing of spectral signals (Figure 3.3C).  This suggests that 
ICG is not covalently associated with the AuNP surface, and cluster assembly is likely 
the result of noncovalent interactions such as hydrophobic self-assembly.  We also 
examined the clusters’ optical properties in aqueous solutions (Figure 3.1E; Figure 
3.3A,B).  Interestingly, the peak associated with clustered AuNPs demonstrated only a 
very modest red-shift compared to the dispersed 2-nm AuNPs, despite the well-studied 
impact of AuNP aggregation on surface plasmon resonance.[40]  To confirm this effect, 
we synthesized control AuNP clusters that are encapsulated with an amphiphilic 
polymer, poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-PCL), instead of ICG.[37]  
These polymer-AuNP clusters, which shared a similar size and structure as ICG-AuNP 
clusters (Figure 3.2C,D), displayed an equivalent absorbance peak, suggesting this is a 
shared feature of these nanostructures.  When examining cluster absorbance peaks, we 
also found that ICG demonstrated strong quenching when incorporated into this cluster 
formulation, as observed by a reduction in fluorescence compared to equivalent 
concentrations of free ICG.  This likely results from a combination of mechanisms, 
including self-quenching of ICG as a result of its tight packing on the surface of the 
clusters, and quenching due to the close proximity of ICG to the AuNPs, as gold is 
known to be an extremely effective quencher.[41,42]   
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Figure 3.3.  (A) and (B) Absorbance and fluorescence spectra, respectively, of ICG-AuNP clusters (3 µg mL-
1 ICG, 20 µg mL-1 Au) and equivalent concentrations of free ICG, dodecanethiol AuNPs, and polymer-AuNP 
clusters.  Separate spectra were collected in water, dimethylformamide (DMF), and toluene.  (C) ICG-AuNP 
clusters (3.4 µg mL-1, 23 µg mL-1 Au), dissolved in DMF and then centrifuged; the precipitate was then 
dissolved in an equivalent volume of toluene. 
In order to optimize cluster composition and yield, we synthesized a number of 
different formulations of clusters by varying the relative amounts of ICG and AuNPs 
(Figure 3.4; Table 3.1).  As expected, increasing the concentration of AuNPs relative to 
ICG resulted in more of the reagent ICG being successfully incorporated within clusters, 
maxing out at approximately 70% ICG encapsulation efficiency.  Within the column-
purified clusters, the ratio of ICG to Au was quite consistent across all nanoformulations 
tested, with ICG mass approximately 5-10% compared to gold mass.  We also observed 
that using a larger initial ratio of AuNPs caused a moderate increase in cluster size, 
despite the consistent proportions of ICG and Au.  Ultimately, we determined that the 
optimal cluster composition consisted of 2:16 ICG:AuNP (w/w) loading; this yielded 
efficient incorporation of ICG relative to starting material, high loading of ICG relative to 
Au, and favorable hydrodynamic diameter. 
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Figure 3.4.  Multiple cluster formulations were synthesized by varying the ratio of ICG to AuNPs.  ICG 
concentration was determined by absorbance, following dissolution in organic solvent; Au concentration was 
determined by ICP-OES.  Black marker indicates the formulation selected for all other experiments.  (A) 
Encapsulation efficiency of ICG into particles, which was calculated by dividing the ICG:Au ratios of the 
reaction solutions after vs. before column purification (expressed as percentage).  (B) Loading efficiency of 
ICG within the purified particles, as calculated by the ICG concentration divided by Au concentration 
(expressed as percentage).  (C) Hydrodynamic diameter of the particles.  n = 2 particle batches, ± SEM. 
mg ICG: 
mg AuNPs 
Encapsulation 
Efficiency (%) 
ICG 
Loading (%) 
Hydrodynamic 
Diameter PDI a 
2:4 9.24 ± 1.19 7.52 ± 1.78 37.42 ± 5.98 0.138 
2:6 10.61 ± 0.36 5.56 ± 1.00 45.02 ± 0.04 0.116 
2:8 19.92 ± 1.30 7.91 ± 1.00 49.31 ± 4.36 0.133 
2:10 30.49 ± 14.16 7.74 ± 2.20 46.69 ± 5.54 0.138 
2:12 35.53 ± 6.45 9.16 ± 1.21 54.81 ± 2.25 0.148 
2:14 47.18 ± 18.11 8.09 ± 1.61 55.65 ± 5.09 0.144 
2:16 67.83 ± 15.21 9.82 ± 0.28 61.22 ± 2.63 0.138 
2:18 55.70 ± 4.08 8.41 ± 0.24 59.98 ± 2.33 0.124 
2:20 70.19 ± 7.72 7.97 ± 0.44 68.92 ± 9.29 0.149 
 
Table 3.1.  Summary of Figure 2.  Multiple cluster formulations were synthesized by varying the ratio of ICG 
to AuNPs.  Encapsulation efficiency of ICG was calculated by dividing the ICG:Au ratios of the reaction 
solutions before vs. after column purification (expressed as percentage).  ICG loading was calculated by the 
ICG concentration divided by Au concentration (expressed as percentage).  Hydrodynamic diameter is 
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expressed in nanometers.  Bolded text indicates the formulation selected for all subsequent experiments 
(2:16).  n = 2 particle batches, ± SEM. 
In Vitro Imaging of ICG-AuNP Clusters 
Aqueous solutions of clusters and free ICG were prepared in a range of 
concentrations that were loaded simultaneously into imaging phantoms.  We found that 
clusters displayed intensity-dependent signal for both fluorescence imaging and 
photoacoustic imaging (Figure 3.5).  Notably, clusters demonstrated strong quenching 
of fluorescence signal compared to free ICG; in contrast, photoacoustic signal intensity 
was amplified in the nanoformulation, particularly at lower concentrations.  These 
complimentary phenomena can likely be explained by the tight packing of ICG and Au 
within the cluster structure: close molecular proximity promotes collisional/self-
quenching, decreasing the proportion of energy emitted radiatively (as fluorescence) and 
increasing nonradiative emission (heat, read as ultrasonic emissions). [42–44]   We also 
collected photoacoustic spectra for polymer-AuNP clusters, knowing that many Au 
nanoformulations generate photoacoustic signals.[5,13,16,24]  These spectra suggest that 
the polymer-AuNP cluster is only able to generate a modest photoacoustic signal 
intensity within the NIR range, with decreasing intensity at longer wavelengths.  This 
corresponds with our data showing that ICG-AuNP clusters have similar PA spectra 
compared to free ICG, with only a slight increase in signal due to the presence of the 
AuNPs. 
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Figure 3.5.  Phantom imaging of ICG-AuNP clusters in water vs. equivalent concentrations of free ICG and 
polymer-AuNP clusters.  (A) Fluorescence imaging (ex = 745, em = 820).  (B) Quantification of fluorescence 
signal intensity (radiant efficiency) as a function of ICG concentration.  (C) Photoacoustic imaging (PA gain 
30-40 dB, priority 95%, distance 12 mm from the transducer; transducer axial resolution, 75 µm; broadband 
frequency, 13-24 MHz).  (D) Complete PA spectra at varying concentrations.  ICG-AuNP clusters and free 
ICG are expressed as µg mL-1 ICG; polymer-AuNP clusters are shown at a gold dosage equivalent to that of 
the 25 µg mL-1 ICG-Au clusters (167 µg mL-1 Au).  (E) Quantification of PA signal intensity (810 nm) as a 
function of concentration, compared to cluster concentration of ICG (shown) or Au (equivalent). 
In Vitro Heating and ROS Generation of ICG-AuNP Clusters 
Next, we examined the ability of clusters to generate heat upon irradiation.  
Solutions of clusters in water and control solutions were treated with 808nm laser light 
ICG 
Clusters 
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(1.2 W power, 0.1 cm2 area), and temperature was recorded over time.  Clusters were 
found to generate significant temperature increases, higher than that of free ICG at 
every concentration tested (Figure 3.6A).  When solutions were irradiated in multiple 
successive rounds, free ICG showed rapid degradation of its heating capacity, while 
clusters showed repeated heating ability through multiple laser administrations (Figure 
3.6C).  Clusters were also dissolved in serum containing biologically-relevant 
concentrations of hemoglobin, to compare their heating capacity relative to biological 
chromophores (Figure 3.6B).  Even at low cluster concentrations, clusters showed 
significant and additive heating compared to hemoglobin alone, suggesting an 
appropriate safety window could be attained in vivo. 
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Figure 3.6.  Solutions of ICG-AuNP clusters, free ICG, and various controls were prepared at room 
temperature and then irradiated at 808nm (1.2 W power, 0.1 cm2 area) continuously for 10-30 minutes.  (A) 
Solutions in water; final solution temperature is plotted.  (B) The temperature of water; fetal bovine serum; 
clusters (0.0015 mg mL-1 ICG) in water; hemoglobin (155 mg mL-1) in fetal bovine serum; and clusters and 
hemoglobin dissolved in serum at noted concentrations and heated for the indicated times.  (C) Solutions in 
water (0.015 mg mL-1 ICG), heated in multiple 10-minute increments and allowed to cool to room 
temperature between successive rounds.  (D) and (E) Clusters and free ICG (0.015 mg mL-1) were irradiated 
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in the presence of Singlet Oxygen Sensor Green, which detects formation of reactive oxygen species.  
Controls included the following: samples containing sodium azide (10 mM), a known scavenger of singlet 
oxygen; and non-irradiated samples heated to equivalent temperatures by external heat application.   
ICG nanoformulations have been well studied both in photothermal therapy and 
in photodynamic therapy, with many reports of dual activity for a single particle.[26,27,32,34]  
To this end, ICG-AuNP clusters were also examined for their ability to produce reactive 
oxygen species (ROS), which was monitored using the fluorescent reporter dye Singlet 
Oxygen Sensor Green (SOSG) (Figure 3.6D,E).  Irradiated clusters demonstrated a 
strong time-dependent increase in SOSG signal.  As observed in thermal studies, 
clusters and free ICG showed similar activity during the initial moments of irradiation, but 
free ICG appeared to exhaust its capacity more quickly.  Further experiments confirmed 
that the SOSG fluorescence signal was unchanged in the absence of irradiation, even 
when equivalent levels of heat were applied directly to the solution.  Moreover, we found 
that the SOSG signal was strongly reduced in the presence of sodium azide (10 mM), 
which is a known scavenger of singlet oxygen.  Altogether, this provides strong evidence 
that ICG-AuNP clusters can generate ROS and provide a combination of photodynamic 
and photothermal therapy. 
Cell Cytotoxicity of ICG-AuNP Clusters 
After thorough physiochemical characterization of ICG-AuNP clusters in 
nonbiological conditions, clusters were next examined for cytotoxicity in cell culture.  For 
these studies, we selected mouse 4T1 mammary carcinoma cells as a clinically relevant 
model of highly-aggressive, triple negative breast cancer.[45]  Cells were incubated with 
increasing concentrations of clusters and free ICG, after which cellular viability was 
quantified by MTT assay (Figure 3.7).  No toxicity was observed under standard dark 
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conditions, as evidenced by > 95% cell viability compared to media-only controls, even 
up to the highest concentration tested (10 µg mL−1 ICG).  However, in parallel 
experiments, cluster treatment was combined with laser irradiation (0.2 W cm−2, 7 
minutes); under these conditions, cytotoxicity dropped sharply at a cluster concentration 
of 10 µg mL−1, resulting in nearly complete loss of cell viability (reduced to 5%).  
Furthermore, this effect did not extend to free ICG, which showed only a moderate 
decrease in viability (down to 69%).  These results suggest that ICG-AuNP clusters 
would be both well-tolerated systemically and highly effective at killing laser-targeted 
tissues. 
  
Figure 3.7.  MTT assay of 4T1 cells incubated with ICG-AuNP clusters, free ICG, or standard media for 24 
hours.  A subset of cells was irradiated at 808 nm (0.2 W cm-2) for the first 7 minutes.  n = 3 wells, ± SEM. 
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In Vivo Biodistribution and Toxicity of ICG-AuNP Clusters 
We next sought to understand how ICG-AuNP clusters would behave in vivo 
under non-treatment conditions.  First, we administered clusters to healthy mice (30 mg 
kg−1 Au, 4.5 mg kg−1 ICG, I.V.) and measured gold content in the blood beginning at 5 
minutes post-injection and lasting through the first 24 hours (Figure 3.8A).  Clusters 
showed an approximate blood half-life of 61 minutes; for comparison, non-nanoparticle 
ICG has been previously reported to have a blood half-life of approximately 3 min.[46] 
 
Figure 3.8.  ICG-AuNP clusters (30 mg kg-1 Au, 4.5 mg kg-1 ICG, I.V.) were administered to naïve C57BL/6 
mice and biodistribution was determined in key tissue compartments by ICP-OES analysis of gold.  Results 
expressed as percent injected dose per gram tissue.  (A) Blood pharmacokinetics for the first 24 hours post-
injection.  (B) Tissue biodistribution for the first 28 days post-injection. n = 3 mice per timepoint, ± SEM; 
urine and feces represent one sample each, pooled from three mice. 
Next, we examined long-term biodistribution by measuring gold content in tissues 
(Figure 3.8B).  Clusters displayed a tissue biodistribution pattern that is typical for gold 
nanoformulations, with high accumulation in the liver (34.8 ± 13 %ID g−1, day 1) and 
spleen (25.6 ± 2.4 %ID g−1, day 1).  Gold accumulation was low (< 3 %ID g−1) in all other 
analyzed tissues, including brain, heart, kidney, and lung, and remained low over the 
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course of the four-week study.  Although elimination from the spleen remained 
protracted, we found that the levels of gold in the liver decreased steadily, dropping over 
3.5-fold over time.  These results can likely be attributed to the particle design -- 
specifically, that the incorporated gold comprises clusters of discrete ultrasmall AuNPs 
rather than a large, solid core.  Notably, during this time period, gold could be detected 
in the feces, suggesting that elimination occurred through the hepatobiliary system. 
Throughout this study, we examined several broad markers of toxicity.  Animals 
displayed no signs of illness, distress, or other behavioral alterations.  Animal body 
weight showed a small, insignificant decrease in the first several days, likely due to the 
effects of injection and blood collection, but recovered fully over the course of four weeks 
(Figure 3.9A).  We also evaluated histology of key organs – liver, spleen, and kidney – 
but found no evidence of pathology (Figure 3.9B). 
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Figure 3.9.  ICG-AuNP clusters (30 mg kg-1 Au, 4.5 mg kg-1 ICG, I.V.) were administered to naïve C57BL/6 
mice.  (A) Mouse body weights were recorded serially for three mice.  Results expressed as ± SEM.  (B) 
Organ samples (liver, spleen, and kidney) were collected from mice at 1 day, 3 days, 7 days, and 14 days 
post-injection; tissues were fixed in formaldehyde, embedded in paraffin, stained with H&E, and examined 
for histology.  Representative images from days 1 and 14 are shown. 
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Finally, we assessed the short-term accumulation of clusters in murine orthotopic 
tumors.  For these and subsequent studies, 4T1 mammary tumors were implanted 
orthotopically in immune-competent mice.  When tumors surpassed 50 mm3, mice were 
injected with ICG-AuNP clusters (20 mg kg−1 ICG, 133 mg kg−1 Au, I.V.).  Eighteen hours 
later, we found 1.95 ± 0.4 %ID g−1 had accumulated in the tumor.  This is consistent with 
previously reported results for nanoparticle tumor accumulation.[47] 
In vivo Imaging of ICG-AuNP Clusters 
Having established in vivo tolerability of ICG-AuNP clusters, we next prepared to 
evaluate their diagnostic and therapeutic potential in a mouse orthotopic breast cancer 
model.  We first sought to visualize tumors by photoacoustic imaging using accumulated 
ICG-AuNP clusters as a contrast agent.  Tumor-bearing mice were imaged both at 
baseline and 18 hours after receiving either clusters or free ICG (20 mg kg−1 ICG, 133 
mg kg−1 Au, I.V.) (Figure 3.10; Figure 3.11).  Cluster-treated mice demonstrated high 
signal intensity localized to the tumor; this signal was spectrally distinguishable from 
background photoacoustic signal contributed by oxygenated and deoxygenated 
hemoglobin.  In contrast, mice who received free ICG showed very little overall signal.  
These data correlate well with previous reports showing rapid clearance of ICG from the 
body,[46] and emphasize that nanoformulations of ICG broaden its tissue imaging 
applications. 
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Figure 3.10.  Photoacoustic imaging of 4T1 orthotopic mammary tumors in mice receiving either free ICG or 
ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.).  (A) Representative images of mouse tumors at 
18 hours post-injection.  Left, ultrasound image; right, spectrally unmixed photoacoustic (color) image of 
ICG/cluster distribution (yellow) as well as oxygenated (red) and deoxygenated (blue) hemoglobin signal.  
(B) Quantification of PA signal intensity before injection and 18 hours after injection; left bars show total PA 
intensity, right bars show intensity associated with spectrally unmixed ICG/cluster signal.  n = 3 mice per 
group, ± SEM. 
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Figure 3.11.  Photoacoustic imaging of 4T1 orthotopic mammary tumors in mice receiving either free ICG or 
ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.).  Images were collected both prior to injection and 
18 hours post-injection, with columns matched for individual mice. Within each box, ultrasound images (left; 
gray) are displayed next to spectrally unmixed photoacoustic images (right; yellow = clusters/ICG, red = 
oxyhemoglobin, blue = deoxyhemoglobin). 
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In vivo Heating of ICG-AuNP Clusters 
Finally, we evaluated antitumor efficacy in a photothermal therapy model.  In 
these studies, we delivered irradiation subcutaneously using a surgical model.  Mice with 
established 4T1 tumors (50 mm3) were treated with either saline, free ICG, or ICG-AuNP 
clusters (20 mg kg−1 ICG, I.V.); eighteen hours later, mammary tumors were exposed by 
skin incision and directly irradiated for 30 minutes (0.7 W cm−2, 1.13 cm2 laser area).  
During irradiation, we observed an increase in tumor temperature for all groups (Figure 
3.12A,B).  However, cluster-treated mice demonstrated the most profound heating 
effect, ultimately rising approximately 13 °C above body temperature (13.4 ± 2.3 °C).  In 
contrast, tumor temperature rose only moderately in saline- and free ICG-treated 
animals (6.4 ± 0.9 °C and 6.7 ± 0.8 °C, respectively).  Indeed, free ICG appeared to 
improve hyperthermia very modestly at early timepoints – though still less than ICG-
AuNP clusters – but the effect was not sustained; this observation coheres well with our 
in vitro data showing a rapid plateau of heating capacity (Figure 3.6A,B). 
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Figure 3.12.  Mice bearing 4T1 orthotopic breast tumors were injected with saline, free ICG, or ICG-AuNP 
clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.); eighteen hours later, a subset of mice also received 
subcutaneous laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes).  n = 5 mice per group, for a 
total of six groups.  (A) Representative thermographic image during treatment.  (B) Quantification of thermal 
imaging data over time, expressed as the difference between tumor temperature and animal body 
temperatures (average temperatures in fixed-size regions of interest).  (C) Tumor growth curves, averaged 
among groups; day -1 = injection, day 0 = laser treatment or no treatment.  (D) Kaplan-Meier curve 
demonstrating animal survival.  Data shown ± SEM; * = p < 0.05; n.s. = no statistical significance. 
Mammalian cell death typically occurs at temperatures > 42-44 °C, though this 
effect is contingent on duration of heating as well as other factors such as cell type. [48]  
We observed that cluster-treated tumors surpassed 43 °C within 5 minutes of heating, 
reaching an ultimate recorded temperature of 52.3 ± 2.3 °C by 30 minutes (Figure 3.13).  
This was a marked improvement over both control groups, which required more than 10 
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minutes to exceed 42 °C and which attained significantly lower final temperatures (free 
ICG: 45.6 ± 1.4; saline: 43.6 ± 1.2 °C).  It is important to note that tumor hyperthermia 
was observed using an infrared thermographic camera, which detects surface 
temperature of tissues but cannot fully characterize the thermal environment within the 
tumor. 
 
Figure 3.13.  Quantification of thermal imaging data from mice bearing 4T1 orthotopic tumors, treated with 
saline, free ICG, or ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.), and then treated with 
subcutaneous laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes) eighteen hours later.  Data 
show the maximum temperature observed in the tumor for each group.  n = 5 mice per group, for a total of 
three groups, ± SEM. 
We next tracked long-term tumor growth in these photothermally-treated mice, as 
well as in control mice receiving drugs or saline alone (Figure 3.12C; Figure 3.14).  We 
observed statistically significant tumor shrinkage in mice that received the therapeutic 
combination of ICG-AuNP clusters with laser irradiation.  This response was robust: 
average tumor size regressed below pre-treatment volume within two days of therapy, 
continued to drop until Day 6, and remained below the initial volume for a total of 11 
days.  Only one other experimental group displayed regression – those receiving free 
ICG and laser therapy together – but this decrease was brief (one day) and modest (did 
101 
 
not reach pre-therapy size).  ICG-mediated PTT was not significantly more effective than 
controls at any time.  In contrast, PTT with ICG-AuNP clusters showed significant 
improvement over PTT with ICG (p < 0.05, day 6 onward) as well as PTT-alone, 
clusters-alone, ICG-alone, or no treatment (p < 0.05, day 2 onward). 
 
Figure 3.14.  Individual tumor growth curves for all 4T1 tumor-bearing mice receiving injections of saline, 
free ICG, or ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.).  A) Mice receiving drugs alone; day -
1 = injection.  B) Mice receiving drugs plus laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes) 
eighteen hours after injection; day 0 = laser treatment. 
When comparing all treatment groups to the control (saline with no PTT), we 
found a significant improvement in animal survival for mice receiving clusters and laser 
irradiation (p = 0.032); no other group showed statistical significance (Figure 3.12D).  
Notably, two out of five mice that received cluster-mediated PTT displayed complete 
remission of the primary tumor (Figure 3.14B).  One of these mice died on Day 22, 
potentially of a tumor metastasis, which is common for this model[45] and which was 
102 
 
supported by an observation of 15% body weight increase, suggesting ascites; however, 
the other mouse survived until termination of the study on Day 60, indicating full disease 
remission. 
3.4 Conclusion 
We set out to create a nanoformulation incorporating two common and well-
characterized materials: indocyanine green, a clinically-approved dye, and gold 
nanoparticles, which are also utilized in ongoing clinical trials.  We found that these two 
materials formed a stable nanocluster structure – despite the absence of additional 
binding or solubilization reagents – and demonstrated excellent in vitro and in vivo 
biological interactions, including low toxicity, effective tumor localization, and good 
excretion over time.  Knowing that both ICG and AuNPs are highly effective in 
photoacoustic imaging and photothermal therapy, we set out to characterize ICG-AuNP 
clusters in these modalities.  Both in vitro and in vivo data indicated that the 
nanoparticles are potent and specific imaging reagents, and are highly effective at heat 
production.  We found that mice treated with clusters and laser irradiation – but not those 
with free ICG and laser – could exhibit severe tumor cytotoxicity in a triple-negative 
orthotopic breast cancer model; this included 40% complete remission of the primary 
tumor and 20% complete remission of disease.  Altogether, these ICG-AuNP clusters 
represent a promising new nanomaterial for cancer diagnosis and therapy. 
3.5 Experimental Section 
Materials:  Indocyanine green, gold (III) chloride trihydrate, tetraoctylammonium 
bromide, 1-dodecanethiol, sodium borohydride, Sepharose® CL-4B, and sodium azide 
were purchased from Sigma-Aldrich (St. Louis, MO).  Poly(ethylene glycol)-b-poly(ε-
caprolactone) (PEG4k-PCL3k) was purchased from Polymer Source (Quebec, Canada).  
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Singlet Oxygen Sensor Green Reagent, fetal bovine serum (FBS), Trypsin-EDTA, 
Dulbecco’s Modified Eagle Medium (DMEM), and penicillin-streptomycin solution were 
purchased from Thermo Fisher Scientific (Gibco; Waltham, MA).  MTT assay kit was 
purchased from Roche Diagnostics GmbH (Mannheim, Germany).   
 
Synthesis of 2-nm hydrophobic gold nanoparticles:  Dodecanethiol-coated gold 
nanoparticles were synthesized according to a protocol modified from Brust et al.,[39] as 
previously described.[37,38,49]  A stock solution of gold (III) chloride trihydrate (1 g mL−1) 
was centrifuged at 16,000 x g for 30 minutes to eliminate seeds, and 306 µL of the 
purified solution was diluted into 30 mL water to yield a 30 mM solution.  In parallel, a 50 
mM solution of tetraoctylammonium bromide was prepared by dissolving 2.19 g in 80 mL 
toluene.  These two solutions were combined in an acid-washed flask and stirred 
vigorously, and 201 µL of 1-dodecanethiol was added.  Finally, a 400 mM solution of 
sodium borohydride was also prepared by dissolving 0.378 g in 25 mL water.  This 
solution was slowly and continuously pipetted into the gold mixture over the course of 15 
minutes, and the resultant mixture was allowed to stir for 3 hours.  The organic phase 
was collected and washed as follows: the toluene solution was first diluted in a 6.5-fold 
excess (v/v) of 95% ethanol, kept at –20 °C overnight, centrifuged to collect the 
precipitated nanoparticles, and resuspended in a minimal volume of toluene.  After a 
total of two such wash cycles, the nanoparticle solution was transferred into pre-weighed 
microcentrifuge tubes and the solvent was removed using a centrifugal evaporator 
(CentriVap, Labconco Corporation, Kansas City, MO). 
 
Synthesis of ICG-AuNP clusters:  Dodecanethiol-coated gold nanoparticles were 
dissolved in toluene at a concentration of 40 mg mL−1 (based on dry particle mass).  
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Meanwhile, a second solution was prepared containing indocyanine green (ICG) 
dissolved in dimethylformamide (100 mg mL−1); 20 μL of the ICG solution was then 
diluted into a mixture of dimethylformamide and toluene (30 μL and 60 μL, respectively).  
The diluted ICG was then combined with the primary gold nanoparticle solution (400 μL 
for most studies, or 50-500 μL for a subset of studies).  The resulting mixture was 
pipetted into a glass vial containing 4 mL of water, and the sample was sonicated until a 
homogeneous colloid was observed.  To remove organic solvents, the emulsion was 
allowed to stand overnight to evaporate toluene, then dialyzed in pure water to remove 
dimethylformamide.  For studies requiring the precise determination of bound and 
unbound ICG, nanoclusters were further purified by passing through a Sepharose® CL-
4B column (1.5 x 12 cm), collected as a dark brown band that was visually distinct from 
green ICG; in all other experiments, including cell and animal functional studies, clusters 
were not purified by column.  Finally, clusters were concentrated using a centrifugal 
evaporator, then centrifuged at 400 x g for 10 minutes to remove large aggregates, and 
generally stored at a concentration of 3-4 mg mL−1 for a period of several weeks. 
 
Synthesis of polymeric-AuNP clusters:  As experimental controls, AuNP clusters were 
encapsulated within a polymeric micelle, according to a protocol modified from Al Zaki et 
al.[35]  Briefly, dodecanethiol-coated gold nanoparticles were dissolved in toluene at a 
concentration of 17.5 mg mL-1 (based on dry particle mass).  200 µL of this solution was 
combined with 3.5 mg of poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG4k-PCL3k) and 
sonicated thoroughly to combine.  The resulting solution was pipetted into a glass vial 
containing 4 mL of water, and the sample was sonicated until a homogenous colloid was 
observed.  To remove organic solvents, the emulsion was allowed to stand overnight to 
evaporate toluene.  Clusters were centrifuged once at 400 x g for 10 minutes to remove 
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large aggregates, and then the supernatant was centrifuged twice at 3100 x g for 30 
minutes to sediment desired micelles.   
 
Physiochemical characterization:  Nanoparticles (including dodecanethiol-coated gold 
nanoparticles, ICG-AuNP clusters, and polymeric-AuNP clusters) were characterized by 
a variety of physiochemical techniques.  Gold particles were visualized using transition 
electron microscopy (Tecnai T12, FEI, Hillsboro, OR) to determine core diameter.  
Hydrodynamic diameter and zeta potential of clusters were also examined using 
dynamic and electrophoretic light scattering, respectively (Zetasizer Nano ZS, Malvern 
Panalytical, Malvern, United Kingdom); all DLS data was expressed by particle number.  
ICG-AuNP clusters, free ICG, and dodecanethiol-coated AuNPs were also dissolved in 
water, dimethylformamide, fetal bovine serum, and/or toluene to capture their 
absorbance spectra (Varian-Cary 100 Bio spectrophotometer, Agilent Technologies, 
Santa Clara, CA) and fluorescence spectra (FluoroMax-3 spectrofluorimeter, Horiba 
Jobin Yvon, Edison, NJ). 
To determine the composition of ICG-AuNP clusters, each constituent was 
examined as follows.  ICG concentration was determined by dissolving clusters in 
dimethylformamide (> 95% v/v) and comparing absorbance at ʎ = 792 nm with a 
standard curve for ICG.  Gold concentration was determined using inductively-coupled 
plasma optical emission spectroscopy (ICP-OES; Spectro Genesis, Spectro Analytical 
Instruments, Kieve, Germany).  Briefly, aqueous solutions of clusters (20-200 µL) were 
placed in round-bottomed glass tubes with polytetrafluoroethylene-coated caps.  To this 
was added up to 300 µL of aqua regia (e.g., 75 µL nitric acid plus 225 µL hydrochloric 
acid), and tubes were capped and allowed to stand at room temperature for several 
hours.  Finally, solutions were diluted up to a standard volume and then 
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spectrometrically analyzed.  ICG and Au concentrations in purified clusters were then 
analyzed using the following equations: 
 
Encapsulation efficiency =  
(ICG mass ÷ Au mass) after column purification
(ICG mass ÷ Au mass) before column purification
 × 100 (1) 
 
ICG loading =  
ICG concentration after column purification
Au concentration after column purification
 × 100 (2) 
       
In vitro imaging:  Varying concentrations of ICG-AuNP clusters, ICG, and/or polymer-
AuNP clusters were dissolved in water and then imaged using a phantom.  In one study, 
solutions (50 µl each) were added to a 384-well plate and then examined by 
fluorescence imaging (IVIS Spectrum In Vivo System, Perkin Elmer, Waltham, MA).  
IVIS parameters: excitation, 745 nm; emission, 820 nm; lamp level, high; exposure time, 
0.5 seconds; binning, (M)8; f, 2. 
In a separate study, solutions were placed into polyethylene tubing (0.5-mm 
diameter) submerged in water at a depth of 1-2 cm, and were examined by 
photoacoustic imaging (Vevo Lazr, VisualSonics, Toronto, Canada).  The LZ250 
transducer was utilized (axial resolution, 75 µm; broadband frequency, 13-24 MHz).  
Images were acquired with the following settings: PA gain 30-40 dB, priority 95%, and 
distance 12 mm from the transducer.  ICG-AuNP clusters and free ICG were examined 
within a single imaging session at 30 dB, allowing direct comparison of signal intensities. 
 
In vitro heating:  Solutions of ICG-AuNP clusters, along with various controls, were 
treated with laser irradiation to induce heating.  One milliliter of prepared solution was 
added to a 2-mL microcentrifuge tube, and a fiber optic thermometer (Nomad, Qualitrol-
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Neoptix, Fairport, NY) was inserted 4 mm below the liquid surface.  Solutions were then 
irradiated with an 808-nm laser (OEM Laser Systems, Midvale, UT) at 1.2 W power (0.1 
cm2 area).  Irradiation continued for a period of 10 minutes, during which temperature 
was recorded every 10 seconds.  In a subset of experiments, solutions were first 
irradiated for 10 minutes as described, then freely allowed to cool to their original pre-
irradiation temperature; immediately after reaching this threshold, irradiation was 
repeated for two additional 10-minute cycles with cooling between.  All experiments were 
performed at room temperature and with ambient light. 
 
In vitro ROS generation: ICG-AuNP clusters and various controls were examined for 
their ability to generate reactive oxygen species, using the reporter reagent Singlet 
Oxygen Sensor Green.  SOSG-containing solutions (2.5 mL, 10 µM SOSG) were added 
to a quartz cuvette and mixed continuously by magnetic stirrer for 30 minutes.  Aliquots 
(60 µL) were withdrawn at each of the following timepoints: 0, 1, 5, 10, 20, and 30 
minutes.  Samples were then diluted 20-fold in water, and fluorescence was read by 
fluorimeter (ex = 488 nm; em = 523 nm) and normalized to the 0-minute reading.  
Solutions of ICG-AuNP clusters and free ICG (0.015 mg mL-1) were tested with or 
without sodium azide (10 mM).  Samples were either kept in the dark or were irradiated 
continuously for 30 minutes (808 nm; 1.2 W power, 0.1 cm2 area).  Irradiated samples of 
clusters and ICG also had surface temperature monitored using a FLIR ONE thermal 
imaging camera (FLIR Systems, Wilsonville, OR); based on this data, a subset of 
samples were heated with equivalent temperature and timing under dark conditions 
(heat generated by Varian-Cary 100 Bio spectrophotometer, thermal accessory).  
Sample conditions generating greater than 1.5-fold change in SOSG fluorescence were 
performed in triplicate; all others were performed as single assays. 
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Cell culture:  Mouse 4T1 breast cancer cells (ATCC, Rockville, MD) were cultured in 
DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin 
(100 U mL−1 penicillin, 100 µg mL−1 streptomycin).  Cultures were maintained at 37°C in 
a humidified incubator with 5% CO2.   
 
Cell viability by MTT assay:  To determine cytotoxicity of ICG-AuNP clusters, 4T1 mouse 
breast cancer cells were seeded in 96-well plates (white with clear, flat bottom) at a 
density of approximately 1.0 x 104 per well.  Cells were allowed to incubate overnight, 
and then media was carefully removed from individual wells and replaced with fresh 
media containing nanoclusters or free ICG at various concentrations (n = 3 wells per 
condition).  Plates were then incubated for 24 hours.  Finally, media was removed and 
cells were washed with phosphate buffered saline, then given fresh media and subjected 
to a standard MTT assay.  Results were expressed as % Cell Viability by comparing to 
the average absorbance value (λ = 590) of cells treated with media alone (n = 3 wells 
per plate used). 
Nanocluster cytotoxicity was also examined in combination with laser irradiation.  
In these experiments, to ensure isolation of environmental conditions, cells were plated 
with two empty wells between them.  The following day, plates were removed from 
incubators and placed on a 37°C warming surface to maintain temperature.  Media was 
exchanged for fresh 37°C media containing nanoclusters or free ICG at various 
concentrations (n = 3 wells per condition).  Immediately after addition, wells were 
irradiated with an 808-nm laser (0.2 W cm−2; 1.13 cm2 area) for a total of 7 minutes (84 J 
cm−2).  Plates were returned to the incubator for 24 hours, after which they were washed 
and analyzed by MTT as described.  Results were expressed as % Cell Viability by 
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comparing to the average absorbance value (λ = 590) of cells treated with standard 
media under dark conditions (n = 3 wells per plate used). 
 
Animal and tumor models:  Female mice (C57BL/6 or BALB/c), aged approximately 6-10 
weeks, were obtained from Charles River Laboratories (Wilmington, MA).  All animal 
studies were conducted with approval by the University of Pennsylvania Institutional 
Animal Care and Use Committee, in accordance with AAALAC guidelines and 
accreditation.   Mice were fed standard chow ad libitum unless otherwise noted. 
In a subset of studies, BALB/c mice were inoculated with 4T1 mouse breast 
cancer cells (2 x 106 cells per mouse, 50-80 µL total volume) injected orthotopically into 
the fourth abdominal mammary pad.  At the time of tumor inoculation, abdominal hair 
was removed by application of depilatory cream; all tumor-bearing mice were also 
switched to a low-fluorescence diet (Teklad global 18% rodent diet 2918, Envigo, 
Madison, WI) to avoid interference with subsequent imaging studies.  Tumor size was 
established by first measuring two axes (length and width) with digital calipers, and then 
estimating tumor volume using the following equation: 
 
Tumor volume =  
Length × Width2
2
 (3) 
 
Biodistribution and toxicity in tissues:  C57BL/6 mice were injected I.V. (retro-orbitally) 
with clusters at a dose of 30 mg Au (approximately 4.5 mg ICG) per kg body weight (n = 
15 mice total).  Blood samples (3-20 µL each) were collected from the tail vein at the 
following timepoints post-injection: 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 6 
hours, 12 hours, and 24 hours.  These samples were collected from a total of three mice 
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per timepoint, such that all mice received either one or two blood collections, and all 
groups were randomized with regards to subsequent study arm assignment.  Blood 
samples were pipetted directly into round-bottomed glass tubes and stored at room 
temperature.  Finally, samples were processed and analyzed for gold content using ICP-
OES as previously described, using up to 1000 µL of aqua regia (e.g., 250 µL nitric acid 
plus 750 µL hydrochloric acid).  For normalization purposes, blood samples were 
considered to be 1 µL = 1 mg.  Half-life was determined by fitting a double exponential 
decay curve to the data using MATLAB software (Mathworks, Natick, MA). 
These same mice were sacrificed at the following timepoints post-injection (n = 3 
per group): 1 day, 3 days, 7 days, 14 days, and 28 days.  Urine and feces samples were 
also collected at these timepoints from lightly-restrained mice, and were pooled from 
multiple mice within each group.  At sacrifice, mice were first anesthetized with 
isoflurane (3%, 2 L min−1 O2; isoflurane precision vaporizer, VetEquip, Pleasanton, CA), 
exsanguinated via cardiac puncture, then euthanized by cervical dislocation.  The 
following organs were then extracted (intact whole organs, unless otherwise noted): 
brain, heart, kidneys, liver (approximately 290 mg of right medial lobe), lung, muscle 
(gastrocnemius), skin (approximately 80 mg from femoral region with hair removed), 
spleen.  Tissues were rinsed in phosphate-buffered saline after extraction, frozen until 
ready for analysis, and then examined for gold content using ICP-OES.  Briefly, collected 
tissues were weighed and then transferred into round-bottomed glass tubes with 
polytetrafluoroethylene-coated caps.  To this was added up to 1000 µL of aqua regia 
(e.g., 250 µL nitric acid plus 750 µL hydrochloric acid).  Tubes were lightly capped and 
allowed to stand at room temperature overnight.  Solutions were diluted up to a standard 
volume, then passed through 0.2 µm filters to remove any indigestible material.  Finally, 
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samples were spectrometrically analyzed. For normalization purposes, urine samples 
were considered to be 1 µL = 1 mg. 
To monitor animal toxicity, three of these mice (those ultimately sacrificed at 28 
days) had their body weights periodically recorded.  Also, for mice sacrificed between 1 
day and 2 weeks, small samples of harvested tissue were analyzed for histology.  The 
following organ samples were collected: kidney (n = 3 per timepoint), liver (n = 3 per 
timepoint), and spleen (n = 2 per timepoint).  Tissue was fixed in formalin for 24-48 
hours.  Samples were then embedded in paraffin, sectioned, and stained with H&E by 
the Penn Center for Musculoskeletal Disorders Histology Core (P30-AR069619).  Slides 
were imaged using an EVOS FL Auto Imaging System (Life Technologies) at 20x 
objective, and tissue was examined for markers of pathology including infiltrating 
immune cells, abnormal and multiple nuclei, apoptotic or necrotic events, and disruption 
of tissue architecture. 
In a separate study, BALB/c mice were implanted with orthotopic mammary 
tumors as described (n = 5 mice).  When tumor size surpassed 50 cm3, mice were 
injected I.V. (via tail vein) with clusters at a dose of 20 mg ICG (approximately 133 mg 
Au) per kg body weight.  Eighteen hours after injection, tumor size was recorded again 
and mice were sacrificed as described.  Tumors were extracted intact, frozen until 
further analysis, and finally examined for gold content using ICO-OES. 
 
In vivo imaging:  BALB/c mice were implanted with orthotopic mammary tumors as 
described.  When tumor size surpassed 50 cm3, mice were anesthetized with isoflurane 
(1.8 - 3%, 2 L min−1 O2) and imaged by photoacoustic imaging as described.  On the 
same day, mice were injected I.V. (via tail vein) with clusters at a dose of 20 mg ICG 
(approximately 133 mg Au) per kg body weight; control mice were injected with an 
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equivalent dose of free ICG (n = 3 mice per group, two groups).  Eighteen hours after 
injection, mice were imaged by photoacoustic imaging as described.  Spectral unmixing 
techniques were used to separate the contrast agent signals from background signals 
(i.e., oxyhemoglobin and deoxyhemoglobin) based on their PA spectra. 
 
In vivo heating:  BALB/c mice were implanted with orthotopic mammary tumors as 
described.  When tumor size surpassed 50 cm3, mice were injected I.V. (via tail vein) 
with ICG-AuNP clusters at a dose of 20 mg ICG (approximately 133 mg Au) per kg body 
weight.  Control mice were injected with an equivalent dose of free ICG or with 0.9% 
saline (n = 5 mice per group, three groups). 
Eighteen hours after injection, mice were subjected to subcutaneous 
photothermal therapy.  Briefly, mice were given preoperative analgesia (0.1 mg kg−1 
buprenorphine, S.Q.) and anesthetized with isoflurane (1.8 - 3%, 2 L min−1 O2); body 
temperature was maintained thereafter using a recirculating water pad (Kent Scientific, 
Torrington, CT).  The abdominal skin was sterilized (povidone-iodine and 70% ethanol) 
and a sterile drape was placed.  Next, a curved incision was made medial to the tumor, 
and hemostat clamps were used to draw back the skin and expose the underside of the 
tumor.  Tumors were irradiated at 808 nm for 30 minutes (0.7 W cm−2; 1.13 cm2 laser 
area, which fully covered all tumors; 1260 J cm−2).  After the completion of illumination, 
skin was sutured with nylon and mice were hydrated with subcutaneous saline.  For the 
subsequent 72 hours, mice were monitored at least daily for wound condition and signs 
of distress, and were given additional buprenorphine (0.1 mg kg−1) for the first 24 hours 
and as needed. 
Immediately before and during the described laser therapy, tumor and abdomen 
surface temperature were monitored using a FLIR ONE thermal imaging camera (FLIR 
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Systems, Wilsonville, OR) at the following timepoints: pre-treatment, 5 min, 10 min, 20 
min, and 30 min.  Infrared images were later analyzed for 1) maximum temperature in 
the tumor, and 2) temperature averaged over each of two 1.3 cm2 circular regions of 
interest, one centered on the tumor and one on an area of the shaved abdomen at least 
8 mm away (thus approximating overall animal body temperature). 
In addition to three groups of laser-treated mice, an additional three groups of 
mice (n = 5 mice per group) with size-matched tumors were injected with equivalent 
doses of either ICG-AuNP clusters, free ICG, or saline.  These mice received no 
additional therapeutic interventions.   
Tumor volume was monitored in all six groups and calculated as described, 
beginning a minimum of five days after tumor cell implantation and continuing until 
animal death.  Criteria for animal sacrifice included any of the following: tumor length 
surpassed 15 mm; ulceration of the skin surpassed 7.5 mm; or animal gait was 
considerably impacted.  Animals were also monitored for weight change and body 
conditioning score, changes in eating and elimination patterns, as well as other markers 
of health and behavior. 
 
Statistical analysis: Tumor growth curves were analyzed by type II ANOVA and pairwise 
comparisons of tumor growth slopes, calculated using TumGrowth open-access 
software (https://github.com/kroemerlab),[50] as well as by t-test of daily tumor volume 
means, calculated using Microsoft Excel (Microsoft Co, Redmont, WA, USA).  For 
survival analysis, log-rank test was performed using MedCalc Software (Medcalc, 
Mariakerke, Belgium),[51] comparing all groups to saline. 
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CHAPTER 4: SUMMARY DISCUSSION, FUTURE DIRECTIONS, AND CONCLUDING 
REMARKS 
 
4.1 Summary Discussion and Future Directions 
Biodegradability of clustered gold particles  
 Gold is a highly popular material in preclinical research, possessing a long 
history and a well-explored range of formulations and applications; however, this breadth 
of study has not translated to clinical adoption of gold particles.  While many potential 
explanations exist (e.g., expense of material, concerns of toxicity), it is likely that 
biodegradation – or the lack thereof – plays a major role.  Still, many reports do not 
include an exploration of their material’s long-term clearance capacity.  In this thesis, we 
have considered gold biodistribution to be an indispensable aspect of particle 
characterization and design.  We have formulated our gold nanomaterials using 
ultrasmall gold particles, which have demonstrated capacity for breakdown within the 
body and excretion through hepatobiliary and/or renal routes.  Specifically, this work has 
built on our group’s previous reported formulations.  In these studies, small individual 
nanoparticles are clustered together within a larger micellar construct.  This has the 
advantages of conferring long circulation (optimizing size, presenting an outer 
hydrophilic PEG surface), as well as packing multifunctional materials together (gold with 
iron oxide, iron oxide with dyes), while retaining a facile synthetic process with high 
volumes of functional cargo (encapsulation of hydrophobic materials within micelles).  
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This methodology therefore installs many favorable features of nanoparticles while still 
working towards the goal of biodegradability.   
In our previous nanoformulations using 2-nm gold particles and PEG-b-PCL, gold 
showed far better breakdown than would be expected for large solid gold cores.  We 
then improved upon this by decreasing the size of gold particles to 0.9 nm.  However, we 
still observed a fraction of gold that persisted within tissues long-term.  Notably, within 
several tissues – particularly the liver – we detected that particles cleared steadily during 
early timepoints, but reached a plateau later on.  This is an important observation 
because it demonstrates the overall utility of long-term biodistribution studies to fully 
capture important interactions, and it also highlights a specific deficiency in our particles’ 
clearance abilities.  Based on this observation, we embarked on the current study using 
environmentally sensitive materials, which we believed would further improve gold 
elimination.  We also chose to pursue the study out to the three-month timepoint, and 
once again, we noticed distinct long-term changes in degradation.  Namely, in a 
compartment that had not experienced any early decrease in gold (i.e., the spleen), 
levels began to fall between one and three months after injection.  This clearly 
demonstrates the complexity of nano-bio interactions and the necessity of gathering this 
extended data when time and materials allow.    
During our study, we found that clearance of gold was quite high (86% in liver, 
72% in spleen).  In order to improve even further, several strategies could be employed.  
Although rates of cellular internalization were not examined in detail, it is plausible that 
slow cell uptake contributed to the long-term biopersistence of gold and its “escape” from 
our pH-mediate clearance mechanism.  Therefore, future studies with this particle could 
include formulation changes that help target it into cellular lysosomes.  Opsonization is 
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known to increase uptake by phagocytic cells (though it is also likely to shorten blood 
circulation times), so perhaps the use of a less-stealthy material than poly(ethylene 
glycol) would produce improvements.  Alternatively, because liver clearance was overall 
faster and more extensive than spleen clearance, efforts could be made to shift this 
biodistribution balance through changes like tuning particle surface chemistry as well as 
size.  Such manipulations could likely be performed easily due to the modular nature of 
our polymer micelles; different amphiphilic coatings could be tested without changing the 
AcetalDextran-AuNPs, which already appear to have highly efficient breakdown 
capabilities.   
Importantly, in our analysis of these particles, we did not examine any 
therapeutic or imaging functions, nor did we look at biodistribution of particles into solid 
tumors.  We consider such an analysis to be highly important and do not necessarily 
assume that these particles will be as functional as previous formulations, especially 
considering their less-efficient loading of gold cargos.  However, we are hopeful that this 
material – or other materials inspired by these techniques – could show good therapeutic 
potential. 
Functional applications of clustered gold particles  
 One of the hallmarks and great advantages of nanomedicine is the ability to 
combine multiple functional moieties within the same particle.  This has been 
demonstrated in countless published works describing nanoparticle formulations with 
nearly every imaginable combination of diagnostic and treatment modalities.  Such 
constructs have many benefits, including precise control over relative dosages at target 
locations and the ability to address complementary clinical goals without repeat 
intervention.  The classic example of this paradigm is a nanoparticle that can traffic into 
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solid tumors and enable A) imaging of tumor location and morphology, and B) 
destruction of cancer cells.  With this pairing, tumor ablation (through surgery, 
radiotherapy, etc.) can be pursued more precisely and safely; furthermore, treatment 
effectiveness can often be predicted and confirmed.   
 In this work, we have reported a nanoformulation that combined two highly 
common materials – gold particles and indocyanine green – and explored their efficacy 
for photoacoustic imaging and photothermal/photodynamic therapy.  Our studies did not 
directly integrate these interventions, largely due to a lack of instrumentation capable of 
employing photoacoustic imaging data for guidance of optical irradiation.  Such 
technology could plausibly emerge in the future as each technique is studied further and 
adopted into mainstream clinical practice. 
 The present work joins a cohort of our group’s reported structures (cited 
throughout) that interchange various functional materials, demonstrating the strong 
modularity of our nanoparticle cluster formulations.  Thus far, cores have been 
assembled from gold nanoparticles, iron oxide nanoparticles, and iron oxide doped with 
elements like zinc and manganese; metal particles have been surface-coated with 
alkanes, sugars, and lipids, and their sizes have ranged from 0.9 to nearly 15 
nanometers; and different particles have been encapsulated within the same structure.  
Additionally, the outer coating has been formed from a variety of amphiphilic molecules, 
including long block polymers (> 7000 Da) and small molecules (< 600 Da).  Imaging 
applications have included photoacoustic, CT, MR, and fluorescence/optical; therapeutic 
applications have included photothermal, photodynamic, radiosensitization, and drug 
delivery.  In summary, varying materials can be combined into stable structures that 
often require little revision of experimental protocols, giving easy access to a broad 
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range of specific functional applications.  Furthermore, due to the relative simplicity of 
materials and syntheses, these particles may have advantages in clinical development 
processes including lead-finding and larger-scale manufacturing.  Further research by 
our group will continue to explore a range of materials and applications compatible with 
these structures, and well as their translatability to the clinic. 
4.2 Concluding Remarks 
 Gold nanoformulations have enormous potential to fulfill unmet clinical needs in 
oncology.  Several ongoing clinical studies have shown great promise for gold’s 
biocompatibility and efficacy in applications such as imaging, drug delivery, and 
radiosensitization.  However, continued research is required to answer fundamental 
questions about gold nanoparticles’ pharmacokinetics, long-term safety, and efficacy for 
emerging treatment technologies.  We are hopeful that this work, and subsequent 
studies building upon it, will help diversify and improve therapies available to patients. 
